























patients	with	 Inflammatory	Bowel	Disease	 (IBD)	are	participating	 in	 even	 less	physical	
activity	than	the	general	population.		
Objectives:	 The	 objectives	 of	 this	 study	 are	 to	 investigate	 what	 the	 current	 levels	 of	





of	 patients	 with	 IBD	 in	 Dunedin	 and	 surrounding	 areas.	 Each	 participant	 received	 a	
personalised	 exercise	 programme	 for	 the	 four-month	 intervention	 and	was	 offered	 the	
choice	of	 joining	one	of	two	groups	during	the	study:	either	exercising	unsupervised	for	
four	months	(independent	group)	or	with	an	initial	month	of	optional	supervised	sessions	
then	 three	 further	 months	 unsupervised	 (support	 group).	 Participants	 were	 asked	 to	
complete	 a	 number	 of	 questionnaires	 at	 baseline	 and	 at	 the	 conclusion	 of	 the	 exercise	
programme	 including	 exercise	 preferences	 &	 attitudes,	 International	 Physical	 Activity	
Questionnaire,	Hospital	Anxiety	&	Depression	Scale,	Multidimensional	Fatigue	Inventory,	
Inflammatory	Bowel	Disease	Fatigue	Scale,	the	Inflammatory	Bowel	Disease	Quality	of	life	
Questionnaire,	 and	 Disease	 activity	 indices	 (Harvey	 Bradshaw	 Index	 or	 Simple	 Clinical	
Colitis	Activity	Index).		
Results:	Eighty-two	patients	consented	to	participate	in	the	study	with	seventeen	choosing	
the	 support	 group	 and	 sixty-five	 choosing	 the	 independent	 group.	 Eleven	 participants	
withdrew	and	a	further	thirteen	were	lost	to	follow	up	during	the	study.	Overall	compliance	
to	 the	 study	 was	 55.8%	 using	 intention-to-treat	 analysis	 and	 83.3%	 when	 using	 per-
















and	Dr	Hamish	Osborne.	 Your	 knowledge,	 enthusiasm,	 and	optimism	have	 been	
invaluable	throughout	this	process	and	have	kept	me	moving	forward.		






































































































































































































































































































































































































Zealand	 only	 50%	 of	 the	 general	 population	 meet	 current	 physical	 activity	
guidelines	(3).	Studies	investigating	physical	activity	in	patients	with	Inflammatory	
Bowel	 Disease	 (IBD),	 a	 chronic	 gastrointestinal	 inflammatory	 condition,	 have	







1.1 INFLAMMATORY BOWEL DISEASE 
IBD,	which	 incorporates	 Crohn’s	 Disease	 (CD),	 Ulcerative	 Colitis	 (UC),	 and	 IBD-
unclassified	 (IBD-U),	 is	 a	 chronic,	 inflammatory	 condition	 which	 affects	 the	
gastrointestinal	system	of	humans	(6,	7).	The	disease	is	characterised	by	periods	of	














Because	 of	 the	 nature	 of	 inflammation	 in	 IBD,	 symptoms	 can	 include	 bloody	
diarrhoea,	 weight	 loss,	 and	 abdominal	 pain	 (10).	 CD	 is	 characterised	 by	
complications	including	fistulae,	strictures,	and	abscesses	whereas	UC	can	present	
with	 complications	 such	 as	 ulcer	 haemorrhage	 and	 bowel	 perforation	 in	 severe	
disease	 (10,	 11).	 Additionally,	 extra-intestinal	manifestations	 can	 occur	 in	 up	 to	
25%	of	patients	and	include	arthritis,	ankylosing	spondylitis,	mood	disorders,	and	
non-alcoholic	fatty	liver	disease	(10,	12).		
The	 exact	 aetiology	 of	 IBD	 is	 not	 known	but	 it	 is	 believed	 to	 involve	 a	 complex	
interaction	between	a	persons’	genetics,	 their	environment,	 immune	system,	and	
gut	microbiome	 (11).	To	manage	 IBD,	 and	complications	 that	 arise	 from	 it,	 both	
pharmacological	interventions	and	surgical	treatment	are	employed	(10,	13).		
	
1.1.1 AETIOLOGY AND PATHOGENESIS  
The	exact	aetiology	of	IBD	is	thought	to	be	complex	and	believed	to	originate	from	
an	environmental	trigger	coupled	with	an	abnormal	relationship	between	intestinal	
microbes	 and	 the	 immune	 system	 in	 the	 gut	 of	 an	 individual	who	 is	 genetically	












loci	 associated	 specifically	with	 CD	or	UC	 (18).	 The	 presence	 of	unique	 risk	 loci	
suggests	that	while	many	of	the	biological	mechanisms	involved	in	the	development	
of	both	CD	and	UC	are	similar,	there	are	still	some	exceptions.	These	differences	in	




permeability	 (15,	 17,	 19).	 Two	 important	 genes	 linked	 to	 an	 increased	 risk	 of	
developing	 IBD	 include	 mutations	 in	 the	 NOD2	 gene,	 which	 is	 responsible	 for	









gene-gene	 and	 gene-environment	 interactions	 as	 well	 as	 other	 environmental	
elements	in	the	aetiology	of	IBD	(14,	19).	
	





With	 industrialisation	 comes	 changes	 to	 society	 such	 as	 improved	 sanitation,	
smaller	families,	less	crowded	living	conditions,	a	more	sedentary	lifestyle,	higher	
exposure	to	air	pollution,	and	consumption	of	a	western	diet	(6,	21).	Many	of	these	
risk	 factors	 have	 been	 associated	 with	 an	 increased	 risk	 of	 developing	 IBD,	
therefore	 it	 is	 argued	 that	 westernisation	 may	 play	 an	 important	 role	 in	 the	
aetiology	of	 IBD	(6,	21,	22).	Further	to	 this,	 in	countries	where	westernisation	 is	
rapidly	occurring,	such	as	Korea,	Japan,	and	China,	there	is	also	a	rising	incidence	of	
IBD	 (23).	 Similarly,	 it	 is	 known	 that	 those	 who	 immigrate	 from	 low	 incidence	
countries	to	high	incidence	countries	adopt	the	risk	of	developing	IBD	that	is	found	
in	 the	area	 they	 immigrate	 into	 (24,	25).	Because	 the	genetic	 component	of	 IBD	




The	 role	 this	 hypothesis	 plays	 is	 linked	 to	 the	 correlation	 between	 the	 rising	
incidence	of	IBD,	as	well	as	other	autoimmune	diseases	such	as	asthma	and	type	














who	 have	 never	 smoked	 and	 experience	 a	 worse	 disease	 course	 requiring	



















due	 to	 their	 retrospective	 nature,	 small	 sample	 sizes,	 and	 large	 recall	 bias.	 For	
example,	 Maconi	 et	 al.	 carried	 out	 a	 retrospective	 case-control	 study	 including	
eighty-three	cases	investigating	dietary	factors	and	their	correlation	with	the	risk	
of	developing	IBD	(32).	While	the	study	offered	an	interesting	perspective	on	diet	
and	 its	role	 in	 IBD	development,	such	as	a	high	 intake	of	meat	and	cheese	being	
linked	to	an	increased	the	risk	of	developing	CD,	the	small	sample	size	and	a	long	
recall	period	(over	the	past	five	years)	means	that	the	findings	of	the	study	are	very	
limited.	 Further	 research	 involving	 larger	 sample	 sizes,	 multiple	 countries,	 and	





The	 microbiome	 of	 the	 gastrointestinal	 tract	 of	 a	 healthy	 person	 is	 crucial	 in	
ensuring	the	proper	digestion	of	carbohydrates,	regulation	of	fat	metabolism,	and	
vitamin	 synthesis	 (33).	 However,	 a	 negative	 change	 in	 the	 composition	 of	 the	
microbiome,	also	known	as	dysbiosis,	plays	an	important	part	in	the	pathogenesis	
of	IBD	(33).	In	patients	with	IBD,	there	is	a	25%	reduction	in	the	diversity	of	the	





bacteria	present	 in	 the	gut	(34).	This	results	 in	a	 loss	of	 tolerance	to	commensal	








The	 role	 of	 the	 immune	 system	 is	 to	 resist	 the	 attack	 of	 microbes	 that	 would	
otherwise	 cause	 harm	 to	 the	 host	 (35).	 Both	 the	 innate	 and	 adaptive	 immune	
systems	 have	 been	 implicated	 in	 the	 pathogenesis	 of	 IBD	 and	will	 be	 discussed	
below	(36,	37).		
Innate	immune	system–	
The	 innate	 immune	 system	 in	 the	 gut	 functions	 to	 defend	 against	 pathogenic	
microbia	 and	works	 to	 create	 a	 state	 of	 hypo-responsiveness	 by	 restraining	 the	
inflammatory	responses	to	commensal	bacteria	(19).	Toll-like	receptors	(TLRs)	are	





number	of	T-cell	 co-stimulating	molecules	 (36).	This	means	 that	 there	 is	 a	 large	
influx	 of	 immune	 cells	 to	 the	 intestine	 resulting	 in	 an	 increased	 production	 of	








response	 (36).	 Both	 Th1	 and	Th2	 cells	 recruit	 other	 immune	 cells	 and	 produce	
inflammatory	markers	leading	to	significant	inflammation	in	the	area	where	the	T-
cells	 are	 located	 (11).	 However,	 Th1	 and	 Th2	 cells	 recruit	 different	 cells	 and	











found	 in	 the	 gut.	 In	 IBD,	 patients	 frequently	 have	 a	 compromised	 mucus	 layer	
allowing	bacteria	 to	come	into	contact	with	 intestinal	epithelial	cells	resulting	 in	
excessive	immune	cell	activation,	intestinal	inflammation,	and	increased	intestinal	
permeability	(15,	19).	Similarly,	a	reduction	in	junction	proteins	and	an	increase	in	






1.1.2 PREVALENCE  
No	 nationwide	 study	 has	 been	 conducted	 investigating	 the	 incidence	 and	









in	western	 countries,	 it	 is	 steadily	 increasing	 in	 areas	 of	 the	world	which	 have	
previously	had	lower	incidence	rates	such	as	Asia,	Africa,	and	Latin	America	(20,	
	 11	




1.1.3 SYMPTOMS AND COMPLICATIONS OF IBD 
Both	CD	and	UC	have	a	clinical	course	that	is	marked	by	exacerbation	and	remission	
and	 patients	 may	 experience	 systemic	 symptoms	 including	 malaise,	 anorexia,	
fatigue,	 and	 fever	 (10).	 For	 children	 diagnosed	 with	 IBD,	 growth	 retardation	 is	
common	(10).		
Key	symptoms	for	patients	with	UC	includes	bloody	diarrhoea,	colicky	abdominal	
pain,	 urgency	 to	 pass	 bowel	 motions,	 and	 tenesmus	 (a	 feeling	 of	 incomplete	
defecation)	 (10,	 13).	 Surgery	 in	UC	 patients	 is	 typically	 considered	 curative	 and	
around	 20-30%	 of	 patients	with	 UC	will	 have	 a	 colectomy	 during	 their	 disease	
course	 (13).	 Complications	 that	 may	 result	 from	 UC	 include	 haemorrhage	 from	
ulcers,	 bowel	 perforation,	 and	 toxic	 megacolon	 (a	 severe	 dilation	 of	 the	 large	
intestine	that	can	also	lead	to	perforation)	(10).		
Symptoms	 associated	 with	 CD	 are	 more	 heterogeneous	 but	 typically	 include	
abdominal	pain,	diarrhoea,	 fever,	 and	weight	 loss	(10,	13).	While	not	considered	
curative,	up	to	75%	of	CD	patients	will	require	surgery	 for	 their	disease	at	some	
point	 (13).	 Complications	 that	may	 occur	 from	 CD	 include	 strictures	 (abnormal	
narrowing	of	the	bowel),	fistulae	(an	abnormal	hole	in	the	intestine),	and	abscesses	
(10).	 CD	 causes	 greater	 disability	 than	 UC	 with	 only	 75%	 of	 patents	 with	 CD,	




times	 as	many	 psychological	 symptoms	 than	 those	 in	 remission	 (42).	 The	most	
prevalent	 symptoms	described	 by	 patients	with	 IBD	 are	 a	 lack	 of	 energy,	 bowel	










1.1.4 DIAGNOSIS AND MANAGEMENT  
Diagnosis	–	














Treatment	 for	 IBD	 includes	 medication,	 supplements,	 and	 surgery	 to	 induce	 or	
maintain	remission	(10,	13):	
• Anti-inflammatory	drugs	–	Aminosalicylates	and	Corticosteroids.	These	are	
used	 to	 reduce	 the	 inflammation	 in	 the	 gut	 and	 provide	 relief	 from	
symptoms.	
	 13	
• Immunomodulators–	 Methotrexate,	 Azathioprine,	 and	 6-mercaptopurine.	
These	 are	 used	 to	 modulate	 immune	 response	 or	 the	 functioning	 of	 the	
immune	system.		
• Biological	 therapies	 –	 Infliximab	 and	 Adalimumab.	 These	 are	 used	 as	 a	
second	 line	of	defence	to	 induce	and	maintain	remission	and	are	directed	
against	TNFa.	




• Nutritional	 supplementation	 –	 routine	 multivitamin	 for	 all	 patients,	
additional	vitamin	B12,	vitamin	D,	iron,	or	calcium	supplementation	may	be	
required.	









the	 efficacy	 of	 CAMs	with	 few	 studies	 investigating	 their	 effectiveness	 (43,	 44).	




1.1.5 MONITORING DISEASE ACTIVITY IN IBD 
There	are	several	tools	that	can	be	used	to	monitor	the	activity	of	IBD	in	patients	















of	 recall	 and	omits	body	weight,	haematocrit	 level,	 and	antidiarrheal	medication	
use.	It	can	be	scored	from	0-18	and	has	good	correlation	to	the	CDAI	(47).	
UC	activity	questionnaires	–	
The	 Mayo	 score	 is	 a	 common	 disease	 activity	 instrument	 used	 for	 assessing	 of	
disease	activity	in	UC.	The	composite	instrument	is	scored	on	a	scale	of	0	to	12	and	
includes	 stool	 frequency,	 rectal	 bleeding,	 a	 physician’s	 global	 assessment,	 and	 a	
sigmoidoscopic	evaluation	(45).	An	assessment	tool	which	does	not	require	clinical	






Under	 normal	 conditions,	 CRP	 is	 produced	 by	 hepatocytes	 in	 the	 liver	 in	 low	
quantities	(<1mg/L)	(49).	CRP	is	non-specific	and	increases	in	response	to	any	form	
of	tissue	injury,	infection,	inflammation,	or	malignancy	(50).	CRP	is	often	used	to	
measure	 inflammation	 levels	 as	 analysis	 is	 fast,	 cheap,	 and	 reliable	 (51).	During	
acute	 phase	 stimulation,	 hepatocytes	 rapidly	 produce	 CRP.	 Plasa	 levels	 of	 50-
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200mg/L	 indicate	 severe	 active	 inflammation	or	 bacterial	 infection.	While	 CD	 is	
associated	 with	 a	 strong	 CRP	 response,	 UC	 only	 has	 a	 modest	 to	 absent	 CRP	






range	 from	 0-50µg/g	 (52).	 FC	 has	 a	 high	 specificity	 for	 IBD	 in	 the	 absence	 of	















1.2.1 FATIGUE  
Fatigue	 is	 often	 difficult	 to	 conceptualise	 but	 is	 often	 defined	 as	 extreme	 and	
persistent	 tiredness,	 weakness,	 or	 exhaustion	 –	 either	mental,	 physical,	 or	 both	
(56).	Fatigue	has	been	reported	in	the	general	population	at	high	levels	however,	
patients	 with	 IBD	 report	 fatigue	 levels	 consistently	 higher	 than	 the	 general	
population	(57,	58).		
	
1.2.1.1 MEASURING FATIGUE LEVELS  
The	 lack	 of	 a	 consensus	 on	 the	 definition	 of	 fatigue	 and	 inconsistent	 use	 of	
terminology	 has	 resulted	 in	many	 different	methods	of	measuring	 fatigue	 being	
developed	(56,	59).	A	review	carried	out	by	Hjollund	et	al.	found	that	in	research	
studies	fatigue	had	been	measured	using	252	unique	methods,	with	150	of	those	
only	 being	 used	 once	 (60).	 The	 scales	 used	 for	measuring	 fatigue	 can	 be	 either	
unidimensional	or	multidimensional	and	can	be	used	to	measure	fatigue	levels	in	
many	different	diseases	(56).	Care	must	be	taken	when	choosing	which	scale	to	use	




The	benefit	of	using	a	unidimensional	 scale	 to	assess	 fatigue	 is	 that	 they	 can	be	
completed	quickly	as	they	contain	only	a	small	number	of	questions,	however,	they	







often	 severity	and	 the	nature	of	 the	 fatigue	 (61).	Multidimensional	 scales	which	
have	 been	 used	 in	 patients	 with	 IBD	 include	 the	 Multidimensional	 Fatigue	
Inventory	 (MFI),	 Fatigue	Questionnaire,	 Piper	Fatigue	 Scale,	 Checklist	 individual	
strength,	and	the	IBD-Fatigue	(IBD-F)	scale	(59,	63).		
The	 MFI	 is	 the	 most	 commonly	 used	 multidimensional	 fatigue	 scale	 in	 many	
populations	including	the	IBD	population	(59,	60).	While	it	is	the	most	used	fatigue	
scale	in	IBD	patients	it	has	not	yet	been	validated	for	the	IBD	population	(59).	The	







1.2.1.2 PREVALENCE OF FATIGUE  
A	large	number	of	studies	have	looked	at	the	prevalence	of	fatigue	in	patients	with	
IBD	(5,	58,	62,	63,	67).	In	active	disease,	fatigue	symptoms	can	be	experienced	by	as	
many	as	86%	of	patients	 (67),	however,	up	 to	50%	of	patients	 in	 remission	 still	
experience	debilitating	fatigue	(59,	62,	68).		
There	is	conflicting	evidence	that	those	with	CD	experience	higher	levels	of	fatigue	






stress,	 and	 lower	 HRQoL	 have	 all	 been	 correlated	 with	 higher	 fatigue	 levels	 in	
patients	with	IBD	(59,	63).	
	
1.2.1.3 TREATMENT OF FATIGUE  
Because	of	the	multi-faceted	nature	of	fatigue,	patients	initially	need	to	undergo	a	
series	of	tests	to	identify	if	an	organic	cause	of	fatigue	is	present	(57).	These	include	













(73,	 74).	 Both	 studies	 reported	 a	 significant	 drop	 in	 fatigue	 symptoms	 after	 the	
administration	of	 the	drug.	 It	 is	 thought	 that	 their	positive	effect	on	 fatigue	may	
have	 been	 related	 to	 the	 immune-modulating	effect	 of	 the	 drugs	which	 lowered	
inflammation	levels	and	reduced	inflammation	signalling	in	the	brain	(75).		
A	 previous	 pilot	 study	 in	 Dunedin	 has	 shown	 that	 iron	 supplementation	 was	
effective	 in	 reducing	 fatigue	 levels	 in	 IBD	 patients	 in	 remission	 who	 were	 not	
anaemic	 (62).	 Another	 three	 studies	 have	 taken	 unique	 approaches	 to	 drug	
treatment	for	fatigue.	The	first	looked	at	the	effect	of	a	medicinal	Agaricus	blazei	
murill	mushroom	based	 extract	 on	 fatigue.	 The	 extract	 proved	 to	 be	 effective	 at	
improving	 fatigue	 symptoms	during	 the	 21-day	 duration	 of	 the	 study	 compared	
with	the	control	group	given	a	placebo	(76).	The	second	study	was	a	small	study	
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that	 investigated	 thiamine	 supplementation	 in	 twelve	 fatigued	 IBD	 patients	 in	
remission	and	found	that	83%	of	patients	experienced	complete	remission	of	their	
fatigue	symptoms	after	three	weeks	(77).	A	third	study	investigated	Omega-3	fatty	
acid	 supplementation	 for	 treatment	 of	 fatigue	 over	 twelve	 weeks	 in	 twenty-six	







In	one	study	 involving	 twenty-nine	patients,	 solution	 focused	 therapy	 (SFT)	was	










number	 of	 studies	 assessing	 fatigue	 and	 the	 small	 sample	 sizes	 limits	 the	
applicability	 of	 the	 studies	 to	 the	 wider	 IBD	 population.	 However,	 these	
interventions	do	offer	promising	fields	of	treatment	in	the	future.		
	
1.2.2 HEALTH RELATED QUALITY OF LIFE  
HRQoL	 is	 a	 subjective	measure	 of	 a	 person’s	 perception	 about	 their	 health	 and	




1.2.2.1 MEASURING HRQOL  
HRQoL	can	be	measured	using	either	generic	instruments	or	disease-specific	tools.		








1.2.2.2 CHANGES TO HRQOL  
Several	studies	have	investigated	the	changes	to	HRQoL	in	patients	with	IBD	(82,	










1.2.2.3 TREATMENT TO IMPROVE HRQOL  




TNFa	 medications.	 Studies	 investigating	 the	 effectiveness	 of	 Infliximab	 and	
Adalimumab	 found	 them	 to	 significantly	 improve	 HRQoL	 (73,	 74l,	 90,	 91).	
Importantly,	 one	 study	 showed	 that	 the	 positive	 effect	 was	 sustained	 over	 a	
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significant	period	of	time	(sixty	weeks)	indicating	that	the	modifying	effect	of	the	
anti-TNFa	 treatment	 is	 sustainable	 long	 term	 (73).	 Other	 pharmacological	
treatments	 that	 have	 been	 investigated	 include	 vitamin	D	 supplementation	 (92)	







patient	 orientated	 therapy	 were	 not	 found	 to	 significantly	 improve	 HRQoL	 for	









is	high	 in	New	Zealand	with	15.4%	of	 those	aged	over	 fifteen	reporting	having	a	
medical	diagnosis	of	depression	(3).		
	
1.2.3.1 MEASURING DEPRESSION LEVELS  
There	are	several	questionnaires	designed	to	measure	depression	levels.	The	most	





patients	with	 IBD	 (55,	 102,	 103).	 This	 scale	 is	 often	 employed	 in	 studies	which	
include	 patients	with	 chronic	medical	 conditions	 as	 it	 does	 not	 rely	 on	 somatic	
symptoms	such	as	 insomnia	and	fatigue	which	are	often	present	 in	patients	who	
have	 a	 chronic	 medical	 condition	 but	 who	 are	 not	 depression	 (104).	 The	 BDI	
originally	developed	 in	1961,	 is	one	of	 the	most	widely	used	tools	 for	measuring	





Major	Depressive	 disorder	 and	 as	 a	way	 of	 quantifying	 improvements	 following	
treatment	and	therefore	is	not	meant	to	be	used	as	a	diagnostic	tool	(106).	
	
1.2.3.2 PREVALENCE OF DEPRESSION IN PATIENTS WITH IBD  
A	number	of	studies	have	looked	at	levels	of	depression	in	IBD	patients	(107-110).	
These	 studies	 concluded	 that	 patients	 with	 IBD,	 like	 those	 with	 other	 chronic	
medical	 conditions,	 experience	 higher	 levels	 of	 depression	 than	 the	 general	
population.	A	crucial	study	carried	out	by	Walker	et	al.	showed	that	that	patients	
with	 IBD	 are	 twice	 as	 likely	 to	 experience	 a	major	 depressive	 episode	 than	 the	
general	population	(108).		
Like	with	fatigue	and	HRQoL,	a	small	number	of	studies	have	illustrated	that	those	
with	CD	experienced	higher	 levels	of	depression	 than	 those	with	UC	 (111,	112),	
while	 others	 have	 concluded	 that	 there	 is	 no	 difference	 in	 depression	 levels	
between	 CD	 and	 UC	 patients	 (107,	 113).	 Interestingly,	 a	 two-way	 relationship	
between	disease	activity	and	depression	has	been	described	as	those	with	active	
disease	experience	higher	rates	of	depression	than	those	with	inactive	IBD	(114),	








However,	 there	 are	 a	small	 number	 of	 studies	 investigating	 the	 effect	
of	psychotherapy	 on	depression	 levels	 which	 include	 patients	 who	 were	 not	
clinically	 depressed	 (118-121).	 The	 results	 from	these	studies	 were	 mixed	 with	
some	showing	a	positive	effect	of	the	psychotherapy	(118),	whereas	others	showed	
no	 effect	 on	 depression	 levels	 (119-121).	 While	 psychotherapy	 may	 provide	
beneficial	 short-term	 improvement	 in	 depression	 levels,	 the	 long-term	























1.2.4.1 MEASURING ANXIETY IN PATIENTS WITH IBD 
A	recent	systematic	review	found	the	most	common	scale	used	to	identify	anxiety	
levels	 of	 patients	 with	 IBD	 was	 the	 HADS	 followed	 by	 the	 State-Trait	 Anxiety	
Inventory	(STAI)	(102).	The	HADS	is	often	employed	in	studies	as	it	assessed	both	
anxiety	and	depression	symptoms	but	is	able	to	clearly	distinguish	between	each	




anxiety	 symptoms	 from	 depression	 symptoms	 (124).	 For	 example,	 in	 a	 study	
involving	forty-two	patients	diagnosed	with	either	anxiety	or	depressive	disorders,	








levels	 of	 anxiety,	 often	 which	 is	 higher	 than	 the	 general	 population	 and	 other	
populations	 with	 chronic	 medical	 conditions	 (107,	 108,	 126).	 One	 such	 study	
showed	that	the	percentage	of	IBD	patients	with	a	lifetime	diagnosis	of	any	anxiety	
disorder	was	32%	(108).	The	IBD	population	in	this	study	had	higher	levels	of	panic	









1.2.4.3 TREATMENT FOR ANXIETY  
There	 have	 been	 a	 small	 number	 of	 studies	 investigating	 treatment	 options	 for	
improving	 anxiety	 symptoms	 in	 patients	 with	 IBD	 (103,	 129-132).	 These	
intervention	 studies	 explored	 both	 pharmacological	 and	 non-pharmacological	
treatment	 options.	 Studies	 employing	 pharmacological	 treatments,	 such	 as	 anti-
depressants	 and	 anti-anxiety	 medication,	 showed	 that	 patients	 with	 IBD	
experienced	significant	improvements	in	anxiety	levels	(103,	130).		
A	recent	systematic	review	focusing	on	the	effectiveness	of	psychiatric	treatments	









In	 conclusion,	patients	with	 IBD	experience	a	 significant	 reduction	 to	their	well-
being	including	having	a	significantly	reduced	HRQoL	and	higher	levels	of	anxiety,	












and	 compliance	 to	 exercise	 programme	 interventions.	 As	 this	 thesis	 is	 centred	
around	a	physical	 activity	 intervention,	 this	 section	will	discuss	 these	aspects	 in	
significant	detail.		
	
1.3.1 BENEFITS OF PHYSICAL ACTIVITY 
The	benefits	of	regular	physical	activity	are	wide	and	numerous.	Regular	physical	
activity	 has	 been	 shown	 to	 have	 positive	 effects	 on	 cardiovascular	 health,	
metabolism,	 bone	 health,	 psychological	 well-being,	 and	 functional	 capacity	 of	 a	
person	(1).	Importantly,	with	increased	physical	activity	comes	a	reduction	in	‘bad’	







been	 found	 to	 reduce	 anxiety	 (139,	 140),	 depression	 (139),	 fatigue	 (141,	 142),	
stress	(143),	and	increase	HRQoL	in	the	general	population	(144).		





Concern	 has	 been	 raised	 for	 patients	 with	 IBD	 participating	 in	 high	 intensity	
exercise	as	it	was	thought	that	exercise	may	exacerbate	gastro-intestinal	symptoms	
(147).	However,	several	studies	have	shown	exercise	to	improve	gastrointestinal	
permeability	with	 no	 detrimental	 effect	 on	 disease	 activity	 in	 patients	with	 IBD	
(148-150).	 Additionally,	 exercise	 has	 shown	 to	 reduce	 disease	 activity	 (98,	 99),	




1.3.2 MEASURING PHYSICAL ACTIVITY LEVELS  
There	 are	 several	 factors	 that	 need	 to	 be	 considered	 when	 determining	 what	
method	will	be	most	suitable	for	assessing	physical	activity	of	a	population.	These	
include	 the	 purpose	 of	 the	 assessment,	 the	 population	 being	 measured,	 the	




include	 intensity,	 duration,	 frequency,	 and	 exercise	 type.	While	 one	 tool	may	 be	
effective	at	assessing	the	intensity	and	duration	of	the	exercise,	it	may	be	poor	at	
assessing	 the	 frequency	of	physical	 activity	and	 therefore	will	not	give	a	holistic	
picture	of	how	active	the	person	is.	Secondly,	many	factors	of	a	study	population,	
including	age,	gender,	body	weight,	and	medical	co-morbidities,	affect	the	type	of	
tool	 chosen	 (153).	For	example,	 children,	 adults,	 and	elderly	often	differ	 in	 their	
activity	intensity	as	well	as	their	ability	to	recall	accurately	their	physical	activity	
levels	 (153).	 Therefore,	 when	 deciding	 on	 a	 tool	 to	 measure	 physical	 activity	
considerations	need	to	be	made.		
The	double-labelled	water	method	 is	 the	gold	standard	 for	measuring	metabolic	
rate	 and	 therefore,	 by	 proxy,	 how	 active	 a	 person	 is	 (154).	 This	 method	 uses	
isotopes	of	oxygen	and	helium	to	measure	the	rate	of	turnover	and	the	production	
of	 CO2	 which	 can	 then	 be	 converted	 into	 energy	 units.	 The	 method	 is	 an	 ideal	
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measuring	 the	acceleration	of	 a	person	 in	real	 time.	This	allows	 investigators	 to	
calculate	 an	 accurate	 amount	 of	 physical	 activity	 by	 measuring	 duration	 and	
frequency	 of	 bouts	 of	 activity	 recorded	 by	 the	 accelerometer.	 Because	






up	 periods	 of	 activity	 that	 may	 have	 been	 missed	 through	 other	 methods	 of	
recording	such	as	questionnaires	making	them	an	ideal	objective	measure	(153).	





overestimate	 the	 number	 of	 steps	 due	 to	 a	 large	 force	 being	 detected	 by	 the	
pedometer	(156).		
With	the	rise	of	wearable	technology	use	in	the	community,	heart	rate	monitors	are	
becoming	 increasingly	 common.	 During	 exercise	 an	 increase	 in	 heart	 rate	 is	
recorded	and	by	tracking	this,	an	estimate	of	the	intensity	and	frequency	of	physical	






Self-reported	 questionnaires	 are	 the	 most	 common	 type	 of	 physical	 activity	
assessment	used	in	exercise	intervention	studies	(159).	Advantages	of	using	self-
reported	 questionnaires	 include	 cost-effectiveness,	 ease	 of	 administration,	 and	
good	test-retest	reliability	(153,	160).	However,	one	main	disadvantage	relates	to	
the	 low	correlation	between	self-reported	questionnaires	and	directly	calculated	
physical	 activity	data	 (161,	162).	When	employing	questionnaires,	 time	spent	 in	
vigorous	activity	 is	often	over-estimated	and	 time	spent	walking	 is	often	under-






to	 the	 resting	metabolic	 rate	of	 a	person	 (163).	 It	 can	 be	 calculated	as	hours	or	
minutes.	Therefore,	1	MET-hour	is	the	equivalent	of	sitting	quietly	for	1	hour.		Brisk	
walking	 has	 a	MET	 number	 of	 4,	 so	 therefore	 brisk	walking	 for	 30	mins	 is	 the	
equivalent	 of	 2	 MET-hours	 or	 120	 MET-mins	 (4METs	 x	 0.5	 hours	 or	 4METs	 x	
30mins).	












1.3.3 PSYCHOLOGICAL FACTORS RELATING TO PHYSICAL ACTIVITY  
There	 is	a	significant	gap	between	having	the	 intention	to	exercise	and	a	person	
actually	 exercising	 (165).	 While	 the	 numerous	 benefits	 of	 physical	 activity	 are	
clearly	known,	often	just	informing	a	person	of	these	benefits	is	seldom	enough	to	
cause	 them	 to	 increase	 their	 physical	 activity	 levels	 (166).	 Many	 different	
psychological	factors,	such	as	overcoming	perceived	barriers,	creating	intentions	to	
exercise,	 habit	 formation,	 and	 self-regulation,	 influence	 someone	when	 they	 are	
beginning	to	increase	their	physical	activity	level.		
	
1.3.3.1 BARRIERS TO INCREASING PHYSICAL ACTIVITY  
Seefeldt	et	al.	identified	how	important	overcoming	barriers	is	in	order	for	a	person	
to	 increase	 their	physical	 activity	 level	 (167).	The	 researchers	 reported	 that	 the	
failure	 to	 achieve	 the	 desired	 outcome	 (increase	 in	 physical	 activity)	 can	 be	






(1,	 165).	 Significant	 motivation	 is	 therefore	 required	 to	 begin	 and	maintain	 an	
exercise	programme.		
Failing	to	get	started	 is	another	key	barrier	 to	 increasing	physical	activity	(165).	
When	 a	 behaviour	 is	 not	 part	 of	 a	 person’s	 normal	 routine	 it	 requires	 active	
concentration	 to	 carry	 it	 out.	 This	 contrasts	 behaviour	 which	 is	 routine	 and	
therefore	 requires	 little	 to	 no	 thought	 to	 carry	 out.	 The	 more	 effort	 that	 the	
behaviour	requires	the	less	likely	it	is	to	be	successfully	implemented	as	it	can	be	
easily	 forgotten	 (165,	 168).	 Meta-analysis	 has	 shown	 that	 the	 longer	 the	 time	
between	 the	 intention	 to	 exercise	 and	 actually	 participating	 in	 exercise	 the	 less	
likely	 it	 is	 to	occur	(168,	169).	This	 indicates	 that	remembering	to	act	can	be	an	













1.3.3.2 PERSONAL FACTORS INFLUENCING THE LIKELIHOOD OF EXERCISING 




often	dictates	how	successful	 they	will	be.	Lewis	et	 al.	 investigated	the	 role	self-
efficacy	and	enjoyment	play	in	the	success	of	participants	maintaining	an	exercise	
programme	after	twelve	months	(170).	The	researchers	found	both	were	equally	
predictive	 of	 increased	 physical	 activity	 levels	 at	 twelve	months	 indicating	 that	
those	who	feel	confident	in	introducing	an	exercise	programme	are	often	the	ones	
that	succeed	most.		
Similarly,	 the	stage	of	change	a	person	 is	 in	will	 influence	how	likely	 they	are	to	
participate	 in	a	new	exercise	programme.	The	 five	key	stages	of	change	are	pre-
contemplation,	contemplation,	preparation,	action,	and	maintenance	with	those	in	
the	 pre-contemplation	 or	 contemplation	 stage	 less	 likely	 to	 implement	 a	 new	
behaviour	compared	to	those	in	the	preparation	or	action	stages	(171).	Indeed,	this	



































is	 employed	 there	 is	 a	 higher	 likelihood	 that	 the	 behaviour	will	 be	 successfully	
implemented	(176).	
Implementation	 intentions	 also	 help	 associate	 situational	 contexts	 or	 goal	
opportunities	 with	 the	 corresponding	 desired	 action.	 This	 helps	 to	 achieve	 the	






1.3.3.4 HABIT FORMATION 
Habit	formation	is	described	as	the	process	by	which	an	activity	becomes	automatic	





In	 the	 intention-exercise	 relationship,	 habit	 plays	 an	 important	 part.	Those	who	
have	stronger	habits	are	more	likely	to	carry	out	their	desired	behaviour	than	those	
with	weaker	habits	(179).	This	also	means	that	as	physical	activity	becomes	a	habit,	
a	 person	 no	 longer	 requires	 strong	 intentions	 to	 carry	 out	 the	 action	 as	 it	 has	








article,	Morgan	 calls	 for	 a	 use	 of	 a	 personalised	 approach	when	determining	 an	
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behavioural	 interventions	 focus	 on	 targeting	 key	 behaviours	 to	 change,	 and	
affective	interventions	focused	on	emotional	targets	and	social	support.		
Interestingly,	when	 comparing	different	 types	 of	 educational	 approaches,	 it	was	
found	 that	 a	 brochure	 alone	was	 as	 effective	 as	 providing	 resources	 such	 as	 an	
audiotape	 or	 videotape	 in	 achieving	 high	 compliance	 to	 a	 prescribed	 exercise	
programme	(182).	Further	to	 this,	written	 instructions	were	more	effective	than	
verbal	 instructions	 at	 achieving	 high	 compliance	 to	 a	 physical	 activity	 plan	 for	
patients	with	lower	back	pain.	In	this	study,	the	difference	was	quite	noticeable	with	
77%	 of	 patients	 who	 received	 written	 instructions	 completing	 their	 prescribed	
exercise	 regime	 compared	 to	 only	 36%	 in	 the	 verbal	 instruction	 group	 (183).	
Furthermore,	in	a	study	looking	at	injury	rehabilitation	for	athletes,	those	who	were	
in	 the	 goal	 setting	 group	 had	 higher	 adherence	 rates	 to	 their	 rehabilitation	
programme	than	the	social	support	group	or	the	control	group	(184).	However,	it	
was	important	that	the	goals	set	are	realistic,	as	participants	are	more	likely	to	drop	
out	of	 the	exercise	programme	and	decrease	their	physical	activity	 levels	if	 their	
goals	set	are	inappropriate	(174).		
Factors	 influencing	exercise	 compliance	have	also	been	 investigated.	From	 these	
studies,	 lower	 levels	of	 compliance	 to	exercise	programmes	has	been	associated	
with	older	age,	mental	health	problems,	poorer	physical	health,	and	previous	poor	





1.3.4 PHYSICAL ACTIVITY IN PATIENTS WITH IBD 










1.3.4.2 BARRIERS TO PHYSICAL ACTIVITY  




general	 population	 such	 as	 not	 having	 enough	 time	 to	 exercise	 (167),	 but	 also	
include	other	barriers	that	are	more	specific	to	their	disease,	such	as	abdominal	or	
joint	pain,	disease	 flare-up,	 and	a	 lack	of	 toilet	 access	while	exercising	 (58,	188,	
189).		
	
1.3.5 PHYSICAL ACTIVITY INTERVENTIONS 




Three	 studies	 have	 carried	 out	 one-off	 programmes	 investigating	 the	 effect	 of	
exercise	on	short	term	outcomes	such	as	intestinal	permeability	and	inflammatory	




found	 that	 one	 hour	 of	 high	 intensity	 cycling	 actually	 improved	 intestinal	
permeability	for	patients	with	IBD	(148).	From	these	studies,	it	was	concluded	that	
patients	 with	 IBD	 can	 safely	 participate	 in	 exercise	 without	 causing	 adverse	
symptoms.	 This	 idea	 is	 further	 supported	 by	 Jones	 et	 al.	 who	 carried	 out	 a	









concluded	 that	 physical	health,	 stress,	 general	well-being,	 and	HRQoL	 improved	




































































































































































































































1.3.5.1 COMPLIANCE TO PHYSICAL ACTIVITY INTERVENTIONS  
Compliance	 to	 an	 exercise	 programme	 is	 often	 referred	 to	 the	 degree	 that	 the	
behaviour	of	a	trial	participant	corresponds	to	the	intervention	prescribed	to	them	






There	 are	 two	main	 investigative	methods	 for	 exercise	 interventions.	 Either	 the	
programme	is	supervised/lab-based	or	un-supervised/community-based,	and	each	
option	 has	 its	 own	 benefits	 and	 limitations.	 Traditionally	 higher	 compliance	 is	
achieved	with	a	supervised	intervention	and	a	much	larger	effect	on	the	outcome	is	
often	 observed.	 In	 comparison,	 unsupervised	 or	 community	 based	 exercise	





















IBS	 is	 classed	 as	 a	 functional	 bowel	 syndrome.	 People	 who	 suffer	 from	 IBS	
experience	symptoms	similar	to	those	with	IBD	such	as	abdominal	pain	associated	
with	altered	bowel	movements	and	bloating.	The	main	difference	between	IBD	and	




been	 published.	One	 trial	 investigated	 the	 effect	 of	 yoga	 (196),	one	 the	 effect	 of	









interventions	 and	 used	 some	 form	 of	 aerobic	 exercise	 in	 their	 programme.	
Compliance	rates	for	exercise	interventions	in	CRC	varied	greatly	between	50%	and	
95%	(Figure	4).	Those	with	 supervised	exercise	 interventions	had	a	 compliance	
rate	slightly	higher	than	those	using	an	unsupervised	exercise	programme.	While	
the	 levels	of	compliance	varied	between	studies	 involving	patients	with	CRC,	 the	
compliance	 rates	 seen	 are	 very	 similar	 to	 those	 seen	 in	 the	 supervised	 exercise	
interventions	in	IBD	and	IBS.	(199-211)	
When	 considering	 exercise	 interventions	 for	 IBD,	 IBS	 and	 CRC,	 the	 level	 of	
compliance	 to	 study	 protocols	 varies	 greatly.	 Only	 nine	 studies	 reached	 high	












1.4 STUDY AIMS AND HYPOTHESIS  
While	it	is	known	that	exercise	offers	many	health	benefits,	the	uptake	of	exercise	
by	 the	 IBD	 population	 is	 very	 low.	 This	 study	 will	 provide	 information	 on	 the	
feasibility	 of	 using	 a	 multidimensional	 personalised	 approach	 to	 achieve	 high	
compliance	to	an	exercise	programme	and	determine	if	exercise	as	an	intervention	
will	improve	patients’	well-being.	Additionally,	this	study	will	aim	to	fill	the	gap	in	




• To	 assess	 the	 barriers	 patients	 with	 IBD	 experience	 towards	 exercising,	
exercise	preferences,	current	levels	of	physical	activity,	and	levels	of	fatigue,	
quality	of	life,	depression,	and	anxiety	in	the	community.		








will	 achieve	 high	 compliance	 when	 compared	 to	 other	 unsupervised	 exercise	
programmes	 that	 have	 been	 conducted	 in	 patients	 with	 IBD,	 IBS	 and	 CRC	 (see	





















procedure	 described	 in	 this	 thesis	 were	 approved	 by	 the	 Northern	 B	 Regional	
Health	and	Disability	Ethics	Committee	on	the	10th	May	2017	(HDEC	#17/NTB/44),	
and	 complied	with	 the	 standards	 set	 by	 the	Declaration	 of	Helsinki.	 Participants	
received	 written	 and	 verbal	 explanation	 of	 the	 study	 before	 providing	 written	
informed	consent	(Appendix	1).		
	
2.2 PATIENTS  
Recruitment	 began	 in	 May	 2017	 and	 was	 completed	 in	 August	 2017.	 Potential	
participants	for	the	study	were	identified	either	through	the	Dunedin	Hospital	IBD	
outpatient	clinics	or	through	the	EPISOFTâ	database	(Sydney,	Australia)	containing	
information	 on	 IBD	 patients	 living	 in	 Dunedin	 and	 surrounding	 areas.	 Potential	
participants	who	were	identified	were	either	approached	during	the	outpatient	IBD	







2.2.1 INCLUSION CRITERIA 




















2.3 STUDY PROTOCOL 




appointment	 participants	 completed	 several	 questionnaires	 including	








• Support	 group	 (group	 one):	 Four	 months	 unsupervised	 physical	 activity	
using	 the	 self-designed	 exercise	 programme	 (section	 2.4).	 Optional	 daily	
supervised	 physical	 activity	 sessions	 in	 a	 group	 setting	 during	 the	 first	
month	 of	 the	 intervention	 provided	 to	 participants	 in	 this	 group	 (further	
information	on	these	sessions	are	provided	in	section	2.4).		
• Independent	 group	 (group	 two):	 Four	 months	 unsupervised	 physical	
activity	using	the	self-designed	exercise	programme	(section	2.4).	
Once	participants	had	selected	their	group	for	the	intervention	they	were	asked	to	
provide	a	 reason	why	 they	 chose	 the	 specific	 group.	Each	participant	 received	a	
personalised	 booklet	 outlining	 how	 to	 design	 their	 personalised	 exercise	
programme,	 a	 goal	 chart	 to	 set	 their	 exercise	 goals	 and	 document	 frequency	 of	
exercise,	and	a	packet	of	star	stickers	to	act	as	a	reward	system	for	achievement	of	
goals.		







2.4 EXERCISE PROGRAMME GENERATION 
During	 the	 initial	 clinic	 visit,	 each	 participant	 received	 a	 personalised	 exercise	
programme	which	was	included	in	the	personalised	exercise	booklet	they	received.	











Participants	were	asked	 to	 list	 their	 initial	 fitness	goals	 for	 the	 study	and	
what	they	hoped	to	achieve	during	the	four	months.		
3. Current	or	past	injuries	–	
Through	 conversation	 with	 the	 researchers,	 any	 past	 or	 current	 injuries	
affecting	 their	 participation	 in	 exercise	 was	 ascertained.	 If	 injuries	 were	
significant,	 participants	 were	 withdrawn	 from	 the	 study	 (see	 exclusion	
criteria,	section	2.2.2).		
4. Fatigue	scores	–	
Each	 participant’s	 energy	 levels	 and	 fatigue	 level,	 as	 determined	 using	
fatigue	questionnaires	(section	2.5.5),	were	taken	into	consideration	when	
suggesting	exercise	 type	or	 length	of	 time.	For	example,	 those	with	more	
severe	 fatigue	 levels	 were	 encouraged	 to	 participate	 in	 five	 minutes	 of	
exercise	a	day	to	begin	with.		











the	week	 (specifically	 focusing	on	achieving	exercise	goals,	 their	disease	activity	
	 52	
and	 energy	 levels).	 If	 the	 weekly	 evaluation	 was	 positive,	 participants	 were	
encouraged	 to	 increase	 the	 intensity	 and/or	 length	 of	 time	 of	 the	 exercise	 they	




Participants	who	 chose	 to	 join	 the	 support	 group	 received	 the	 option	 of	 joining	








2.5 ASSESSMENTS  
2.5.1 COMPLIANCE  
In	this	study	compliance	was	measured	as	a	percentage	of	the	number	of	exercise	
sessions	 completed	 by	 the	 participant	 compared	 to	 the	 number	 of	 sessions	
throughout	 the	 trial	 that	 should	 have	 been	 completed	 (a	 total	 of	 80	 sessions	
assuming	 five	 sessions	 per	 week	 over	 16	 weeks).	 Participants	 who	 completed	




2.5.2 PHYSICAL ACTIVITY  
The	IPAQ	short	 form	was	used	to	assess	participants’	 level	of	physical	activity	at	






















well-being,	 abdominal	pain,	number	of	 liquid	stools	and	abdominal	mass	 for	 the	
















2.5.4 ANXIETY AND DEPRESSION  
The	 Hospital	 Anxiety	 and	 Depression	 Scale	 (HADS)	 was	 employed	 to	 measure	
participants’	 anxiety	and	depression	 levels	 (104).	The	HADS	was	 chosen	 for	 this	

















severity	 of	 the	 fatigue	 experienced.	 The	 second	 section	measures	 the	 impact	 of	
fatigue	on	the	patient’s	life.	Both	section	one	and	two	are	measured	on	a	0-4	Likert	
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scale	with	 0	 representing	no	 fatigue/none	 of	 the	 time	and	4	 representing	 severe	
fatigue/all	of	the	time.	The	third	section	contains	unscored	open-ended	questions	
on	possible	factors	influencing	fatigue.		















Copies	 of	 the	 IBD-F,	 MFI	 and	 IBDQ	 are	 available	 in	 Appendix	 8,	 9,	 and	 10	
respectively.		
	
2.5.6 BLOOD AND STOOL SAMPLES 
Blood	test	–	
A	 blood	 test	 was	 completed	 by	 each	 participant	 and	 analysed	 by	 Southern	
Community	Laboratories.	Participants	were	asked	 to	 complete	 the	blood	sample	
within	one	week	of	joining	the	study.	Blood	tests	included:	full	blood	count,	CRP,	













2.5.7 MICROBIOME ASSESSMENT  
At	 both	 baseline	 and	 after	 the	 exercise	 intervention,	 participants	were	 asked	 to	
provide	 stool	 and	 urine	 samples	 to	 analysed	 microbiome	 composition	 and	
metabolic	profiles.	The	urine	sample	collected	was	a	midstream	urine	sample	and	
the	stool	sample	collected	was	a	piece	of	visibly	soiled	toilet	paper.	Both	samples	
were	then	frozen	at	 -80°C	and	will	be	sent	 to	Ontario,	Canada	 for	analysis	by	Dr	
Jeremy	 Burton,	 Deputy	 Director,	 Canadian	 Centre	 for	 Human	 Microbiome	 and	
Probiotic	Research,	Lawson	Health	Research	Institute,	Canada.	The	samples	are	to	




2.5.8 PATIENT INFORMATION 
Patient	notes	were	 reviewed	 for	 further	 information	 if	 indicated,	 for	example	 to	




2.6 STATISTICAL ANALYSIS 
All	statistical	analysis	was	carried	out	using	SPSS,	version	24.0	(IBM	Corp.,	Armonk,	
N.Y.,	USA).	Pearson	Chi-squared	or	Fishers	exact	tests	were	run	when	comparing	
group	 differences	 in	 categorical	 variables.	 Independent	 sample	 t-tests	 or	 Mann	
Whitney	U	 tests	were	 run	when	comparing	 continuous	data	across	 categories.	A	
One-Way	 Analysis	 of	 Variance	 (ANOVA)	 was	 run	 when	 comparing	 continuous	
variables	across	a	categorical	variable	with	more	than	two	groups.	When	there	was	





















































3.2 AIM ONE: 
3.2.1 BASELINE PARTICIPANT DEMOGRAPHICS  
Of	the	eight-two	participants	in	the	study,	forty-five	(54.9%)	were	female	and	89%	
of	participants	were	of	European	decent.	The	mean	age	of	participants	was	45.5	
years	± 16.1	with	 a	 range	 between	 18	 –	 79	 years	 of	 age.	More	 patients	 had	 CD	
(56.1%)	and	the	mean	time	since	diagnosis	was	14.9	years	±	13.0	years.	Almost	80%	
of	 participants	 were	 currently	 taking	 medication	 for	 their	 IBD	 and	 the	 most	
common	 medication	 was	 Aminosalicylates	 (40.2%)	 followed	 by	
immunomodulators	 (34.1%).	 A	 noticeable	 proportion	 of	 participants	 had	 family	
with	IBD	(28.0%)	and	a	third	had	previously	had	surgery	related	to	their	IBD.	Half	
of	the	participants	had	never	smoked	before.		


















Gender,	n	(%)	 Male	 37	(45.1%)	 2	(11.8%)	 35	(53.8%)	 0.0021	
Female		 45	(54.9%)	 15	(88.2%)	 30	(46.3%)	
Age,	mean	±	SD	 45.5	±	16.1	 42.8	±	12.9	 46.2	±16.8	 0.1703	
Ethnicity,	n	(%)	 New	Zealand	
European	
73	(89.0%)	 14	(82.4%)	 59	(90.8%)	 0.1992	
Māori		 3	(3.7%)	 -	 3	(4.6%)	
Other		 6	(7.3%)	 3	(17.6%)	 3	(4.6%)	
BMI,	mean	±	SD		 28.1	±	6.6	 30.4	±	7.1	 27.6	±	6.4	 0.1084	
IBD	type,	n	(%)	 CD	 46	(56.1%)	 7	(41.2%)	 39	(60.0%)	 0.2252	
UC	 32	(37.8%)	 8	(47.1%)	 23	(35.4%)	
IBD-U	 5	(6.1%)	 2	(11.8%)	 3	(4.6%)	
Time	since	diagnosis,	mean	±	SD	 14.9	±	13.0		 15.3	±	11.7		 14.9	±	13.5	 07574	
Currently	on	medication,	n	(%)	 65	(79.3%)	 10	(58.8%)	 55	(84.6%)	 0.0391	
Current	
medications,	n	(%)	
Aminosalicylates	 33	(40.2%)	 8	(47.1%)	 25	(38.5%)	 0.3342	
Biologic	Therapy	 14	(17.1%)	 1	(5.9%)	 13	(20.0%)	 0.1752	
Immunomodulators	 28	(34.1%)	 4	(23.5%)	 24	(36.9%)	 0.2672	
Corticosteroids	 4	(4.9%)	 -	 4	(6.2%)	 0.0812	
Disease	activity,	
mean	±	SD	
HBI	 4.2	±	3.3	 5.4	±	4.59	 4.0	±	3.1	 0.4514	
SCCAI	 3.7	±	2.6	 4.7	±	2.7	 3.4	±	2.5	 0.2184	
Previous	surgery,	n	(%)	 27	(33.3%)	 6	(37.5%)	 21	(32.3%)	 0.6931	
Family	with	IBD,	n	(%)	 23	(28.0%)	 5	(29.3%)	 18	(27.7%)	 1.0002	
Following	a	specific	diet,	n	(%)		 20	(24.4%)	 4	(23.5%)	 16	(24.6%)	 1.0002	
Taking	supplements,	n	(%)	 24	(29.3%)	 8	(47.1%)	 16	(24.6%)	 0.0812	
Smoking	status,	n	
(%)	
Current	Smoker		 14	(17.1%)	 5	(29.4%)	 9	(13.8%)	 0.2142	
Former	Smoker		 27	(32.9%)	 6	(35.5%)	 21	(32.3%)	
Never	Smoked		 41	(50.0%)	 6	(35.3%)	 35	(53.8%)	
Alcohol	
consumption,	n	(%)	
Never	 11	(13.4%)	 2	(11.8%)	 9	(13.8%)	 0.5802	
Less	than	monthly		 19	(23.2%)	 3	(17.6%)	 16	(24.6%)	
2-4	times	per	month	 30	(36.6%)	 9	(52.9%)	 21	(32.3%)	
2-3	times	per	week	 16	(19.5%)	 3	(17.6%)	 13	(20.0%)	
≥4	times	per	week	 6	(7.3%)	 -	 6	(9.2%)	
Physical	activity	
level,	n	(%)	
Low		 28	(34.1%)	 6	(35.3%)	 22	(33.8%)	 1.0002	
Moderate		 42	(51.2%)	 9	(52.9%)	 22	(50.8%)	
High		 12	(14.6%)	 2	(11.8%)	 10	(15.4%)	
Ferritin,	mean	±	SD	 110.8	±	119.7	 86.6	±	50.6	 116.7	±	130.7	 0.8094	
CRP,	mean	±	SD	 4.0	±	6.2	 2.7	±	2.1		 4.4	±	6.9	 0.5814	




3.2.2 PHYSICAL ACTIVITY LEVELS 
At	 baseline,	 the	majority	 of	 participants	were	 in	 the	moderate	 physical	 activity	
category	of	 the	 IPAQ	(51.2%).	The	mean	total	MET-mins	per	week	was	1580.8	± 














Low	 28	(34.1%)	 6	(35.3%)	 22	(33.8%)	 1.0001	
Moderate		 42	(51.2%)	 9	(52.9%)	 22	(50.8%)	
High	 12	(14.6%)	 2	(11.8%)	 10	(15.4%)	
Total	MET-mins/week,		
mean	±	SD	
1580.8 ±	1680.0	 1294.8	±	1255.5	 1656.8	±	1776.5	 0.6342	
Walking	MET-mins/week,	
mean	±	SD	
731.1 ±	1095.9	 645.5	±	681.7	 700.3	±	1112.1	 0.4882	
Moderate	MET-mins/week,	
mean	±	SD		
459.5	±	857.7	 275.3	±	498.0	 493.1	±	925.9	 0.2252	
Vigorous	MET-mins/week,		
mean	±	SD	
583.2	±	1419.4	 374.1	±	795.6	 468.1	±	716.1		 0.5682	








Both	 the	 support	and	 independent	groups	 identified	 similar	 levels	of	barriers	 to	










When	 asked	 about	 their	most	 preferred	 physical	 activity,	walking	was	 the	most	





3.2.3 BASELINE WELL-BEING 




demographic	 values	 to	 investigate	 associations.	 Baseline	 demographic	 variables	
included	age,	BMI,	 time	since	diagnosis,	disease	activity	 indices,	physical	activity	
levels	 (MET-mins/week),	 gender,	 family	 with	 IBD,	 previous	 surgery,	 taking	
supplements,	taking	medication	and	following	a	specific	diet.	
	
3.2.3.1 FATIGUE  

















IBD-F	 Section	one		 8.4	±	3.8	 8.6	±	3.3	 8.3	± 3.9 0.803	
Section	two		 27.0	±	20.6	 34.5	±	24.0	 24.9	± 19.3	 0.155	
MFI	 General	 13.6	±	4.0	 15.4	±	3.7	 13.1	±	4.0	 0.042	
Physical	 12.2	±	4.1	 14.6	±	3.2	 11.6	±	4.0	 0.004	
Reduced	
motivation	
10.2	±	3.6	 11.5	±	3.5	 9.8	±	3.5	 0.091	
Reduced	
activity		
10.0	±	3.8	 11.2	±	3.5	 9.7	±	3.9	 0.117	
Mental		 10.0	±	3.7	 10.2	±	3.7	 9.9	±	3.7	 0.692	





mins/week	 were	 all	 negatively	 correlated	 with	 at	 least	 one	 fatigue	 dimension	




positive	 correlation	 between	 MFI-reduced	 activity,	 rs(36)	 =	 0.414,	 p=0.012.	 See	
Appendix	12,	Supplementary	tables	1	and	2	 for	more	detailed	 information	about	
correlations	between	baseline	variables	and	fatigue	scores.		
Female	 gender,	 having	 family	with	 IBD,	 and	 having	 had	 previous	 surgery	were	
associated	with	increased	fatigue	levels	in	at	least	one	fatigue	dimension	(Appendix	
12,	 Supplementary	 table	2).	Disease	activity	was	 significantly	associated	with	all	














In	 the	 independent	group,	 age,	 vigorous	MET-Mins/week,	 total	MET-mins/week,	
CRP,	 and	 ferritin	 levels	 were	 negatively	 correlated	 with	 at	 least	 one	 fatigue	
dimension.	Female	gender	and	previous	surgery	were	associated	with	 increased	
fatigue	 (Appendix	 14,	 Supplementary	 table	 13	 and	 14).	Disease	 activity	 (HBI	 or	











For	 the	whole	 group,	 there	were	 no	 statistically	 significant	 differences	 in	 IBD-F	
scores	 between	 physical	 activity	 groups.	 MFI-physical	 fatigue	 scores	 were	
significantly	different	for	the	different	levels	of	physical	activity	for	the	whole	group	
(Table	6).	Post-hoc	analysis	showed	a	significant	difference	in	MFI-physical	fatigue	
scores	 from	 the	 low	physical	 activity	 group	 to	 the	 high	 physical	 activity	 groups	






IBD-F	 Section	one	 8.9	±	3.9	 8.3	±	4.0	 8.0	±	3.0	 0.732	
Section	two	 25.7	±	18.8	 27.7	±	23.1	 26.8	±	16.1	 0.925	
MFI	 General	 14.2	±	4.4	 13.2	±	4.0	 13.5	±	3.2	 0.619	
Physical	 13.4	±	3.3	 12.1	±	4.5	 10.0	±	3.0	 0.046	
Reduced	
activity	
10.8	±	3.3	 9.7	±	4.2	 9.1	±	3.1	 0.289	
Reduced	
motivation	
11.2	±	3.0	 9.8	±	4.0	 9.3	±	2.8	 0.227	











IBD-F	 Section	one	 8.5	±	4.3	 8.7	±	3.1	 9.0	±	2.8	 0.985	
Section	two	 27.2	±	21.6	 37.2	±	26.7		 43.5	±	24.7	 0.644	
MFI	 General	 13.8	±	4.7		 15.7	±	3.1		 18.5	±	2.1	 0.313	
Physical	 13.7	±	3.9		 15.6	±	3.0		 13.0	±	2.8	 0.343	
Reduced	
activity	
10.2	±	2.1		 11.6	±	4.5	 12.5	±0.7		 0.673	
Reduced	
motivation	
11.8	±2.9		 11.4	±	4.3		 10.5	±0.7		 0.909	












IBD-F	 Section	one	 9.0	±	3.9	 8.2	±	4.3	 7.8.	±	3.1	 0.659	
Section	two	 25.3	±	18.5	 25.1	±	21.7	 23.5	±	28.5	 0.968	
MFI	 General	 14.3	±	4.4		 12.5	±	4.0	 12.5	±	2.3	 0.251	
Physical	 13.4	±	3.3	 11.2	±	4.4	 9.4	±	2.8	 0.021	
Reduced	
activity	
11.1	±	3.6	 9.2	±	4.1	 8.4	±	3.0	 0.099	
Reduced	
motivation	
10.9	±	3.1		 9.4	±	3.8		 9.0	±	3.1	 0.229	





















Bowel	 55.4	±	8.4	 53.8	±	10.1	 55.8	±	8.0	 0.380	
Emotional	 65.4	±	11.1	 60.6	±	14.0	 66.7	±	10.1	 0.101	
Systematic	 22.9	±	5.6	 20.1	±	5.9		 23.7	±	5.3	 0.017	
Social		 32.1	±	3.4	 30.9	±	4.1	 32.4	±	3.2	 0.108	

















scores,	 rs(17)	 =	 0.515,	 p=0.034.	HBI	 scores	 and	 CRP	 showed	 a	moderate-strong	
negative	 correlation	with	at	 least	one	 IBDQ	dimension.	There	was	no	significant	
difference	 in	 HRQoL	 between	 those	with	 active	 disease	 and	 those	 in	 remission,	
p>0.05,	(Appendix	13,	Supplementary	table	9	and	10).		
In	 the	 independent	 group,	 HBI	 and	 SCCAI	 scores	 showed	 a	 strong	 negative	
correlation	with	all	aspects	of	the	IBDQ,	p<0.01.	Active	disease	state	and	having	had	
































Total	 177.4	±	23.9	 174.8	±	25.7	 176.2	±	21.2	 0.911	
Bowel	 56.0	±	7.6	 54.9	±	9.3	 56.0	±	7.71	 0.852	
Emotional	 67.0	±	11.5	 64.8	±	11.6	 63.9	±	9.0	 0.640	
Systemic	 22.6	±	6.0	 22.9	±	5.5	 23.5	±	5.5	 0.900	




Total	 175.5	±	23.4	 164.2	±	3.3	 141.0	±	31.1	 0.389	
Bowel	 58.2	± 5.4	 52.3	±	11.2	 47.5	±	16.3		 0.377	
Emotional	 64.0	±	12.6	 61.2	±	15.5		 48.0	±	11.8	 0.392	
Systemic	 21.5	±	6.8		 20.1	±	4.7	 15.5	±	9.2		 0.485	




Total	 177.9	±	24.5	 177.8	±	22.9		 183.2	±	10.4	 0.511	
Bowel	 55.4	±	8.1	 55.9	±	8.8	 57.7	±	4.9	 0.731	
Emotional	 67.8	±	11.4	 65.8	±	10.3	 67.1	±	5.7	 0.764	
Systemic	 22.9	±	5.9	 23.8	±	5.5		 25.1	±	3.3	 0.563	
Social	 31.7	±	4.3	 32.7	±	2.5	 33.0	±	1.9	 0.389	
1	One-way	ANOVA	
	
3.2.3.3 DEPRESSION AND ANXIETY LEVELS 
Overall,	 15.9%	of	 participants	 had	 a	HADS	depression	 score	 greater	 than	 8	 and	
27.1%	of	participants	had	a	HADS	anxiety	score	greater	than	8.	Mean	depression	
scores	were	 3.8	 ±	 3.5	 and	 anxiety	 scores	was	 6.4	 ±	 4.3.	 The	 support	 group	 had	















Anxiety	 6.4	±	4.3	 7.6	±	4.4	 6.1	±	4.2	 0.185	







and	 CRP	 showed	 small	 negative	 correlations	 with	 anxiety	 levels,	 (Appendix	 12	
Supplementary	table	5).	Those	with	active	disease	had	higher	levels	of	depression	
when	compared	to	patients	with	disease	in	remission,	p=0.015.		
In	 the	 support	group,	no	variables	 showed	a	 statistically	 significant	 relationship	























Depression	 3.9	±	3.7	 3.7	±	3.6	 4.1	±	2.6	 0.610	
Anxiety	 4.6	±	3.6	 7.6	±	4.5	 6.4	± 3.5	 0.015	
1	One-way	ANOVA	
	








Depression	 3.7	±	2.9		 6.7	±	4.3		 7.0	±	2.8		 0.304	












Depression	 4.0	±	3.9		 2.9	±	3.0	 3.5	±	2.3	 0.479	




3.3 AIM TWO 
3.3.1 EXERCISE COMPLIANCE LEVELS  
When	 analysing	 compliance	 using	 intention-to-treat	 analysis	 involving	 all	
participants,	the	mean	number	of	sessions	completed	during	the	four	months	was	
49/80,	with	 29%	 of	 participants	 completing	more	 than	 80	 sessions	 (Table	 15).	
Mean	compliance,	assuming	0%	compliance	for	those	that	did	not	return	for	follow-





of	 sessions	 (3	 out	 of	 612	 potential	 sessions)	 being	 taken	 up	 by	 a	 total	 of	 two	
participants.		























between	 the	 support	 and	 independent	 groups	 in	 regard	 to	 the	 total	 number	 of	
exercise	sessions	completed,	p=0.088,	or	compliance,	p=0.178,		
	 76	




















exercise	 intervention	 compared	 to	 the	 end	was	 statistically	 significant,	 p=0.005	







3.3.2 CHANGES TO PHYSICAL ACTIVITY 
One-way	 repeated	 ANOVA	 showed	 a	 large	 increase	 in	 physical	 activity	 for	 all	
categories	 of	 the	 IPAQ	 across	 the	 intervention	 (Table	 17).	 At	 follow-up,	 77%	of	
participants	met	New	Zealand	physical	activity	guidelines,	an	increase	of	12.7%.	
Table	17:	Mean	change	in	physical	activity	(IPAQ)	for	the	whole	group	from	baseline	levels.		








































Low		 22	(38.6%)	 12	(20.7%)	 -	 0.0062	
Moderate	 31	(54.4%)	 30	(51.7%)	 -	




proportion	of	 participants	 in	 the	 low	physical	 activity	 category	 (decreased	 from	
35.4%	to	20.7%	after	 the	 intervention)	and	the	proportion	of	participants	 in	 the	








Table	18	 shows	 the	 changes	 in	physical	 activity	between	 the	 support	group	and	
independent	 group.	 Two-way	 mixed	 ANOVA	 found	 no	 statistically	 significant	




following	 the	 intervention,	 a	 statistically	 significant	 increase	 of	 602.2	 MET-
mins/week,	(95%	CI	213.7-990.8).	There	was	a	statistically	significant	difference	in	
moderate	MET-mins/week	at	the	different	time	points,	F(1,56)	=	4.701,	p=0.035,	
partial	 h2	 =0.081.	 Moderate	 MET-mins/week	 increased	 from	 461.1	 ±	 904.9	 at	
baseline	to	752.4	±	1065.3	at	4	months,	a	statistically	significant	increase	of	266.9	























































































3.3.2.2 BARRIERS TO PHYSICAL ACTIVITY  
Following	 the	 conclusion	 of	 the	 exercise	 programme,	 the	 main	 barrier	 to	
participating	in	more	physical	activity	was	not	having	enough	time	(39.0%).	This	








3.3.3 PREDICTORS OF COMPLIANCE 
Compliance	level	was	compared	to	baseline	characteristics,	physical	activity,	and	














IBD-F	 Section	one	 -0.032	 0.8361	
Section	two	 -0.095	 0.4781	



























3.4 AIM THREE: 
3.4.1 CHANGES TO DISEASE ACTIVITY AND WELL-BEING 





	 Before		 After	 Change	Score		 p-value1		
HBI	(n=31)	 4.4	±	3.7	 3.5	±	3.5	 -0.8	(-1.8	–	0.1)	 0.084	





21).	The	main	effect	of	 time	did	not	 show	a	 statistically	 significant	difference	 in	
disease	activity	 scores	across	 the	 intervention.	The	main	effect	of	 group	did	not	




































time	 did	 not	 show	 a	 statistically	 significant	 difference	 in	 CRP	 across	 the	






Support	(n=10)		 2.4	±	2.2	 1.9	±	1.8	 0.629	 0.500	 0.384	
Independent	(n=48)	 6.5	±	17.9	 3.5	±	4.7	
	 85	
intervention,	 p=0.500.	 Nor	 did	 the	 main	 effect	 of	 group	 show	 a	 statistically	











































MFI	 General		 13.4	±	4.0	 11.5	±	3.9	 -1.8	(95%	CI	-2.8	–	-0.8)	 0.001	
Physical	 12.1	±	4.2	 10.5	±	4.1	 -1.6	(95%	CI	-2.4	–	-0.8)	 <0.0005	
Reduced	
Activity	
9.76	±	3.9	 8.6	±	3.8	 -1.1	(95%	CI	-2.0	–	-0.3)	 0.015	
Reduced	
Motivation		
9.8	±	3.6	 8.1	±	4.0	 -1.8	(95%	CI	-2.6	–	-0.9)	 <0.0005	

















independent	 group.	 Two-way	 mixed	 ANOVA	 found	 no	 statistically	 significant	
interactions	between	the	intervention	group	and	time	on	any	of	the	MFI	sub-scales	







Table	25:	Change	 in	 fatigue	 scores	 (MFI)	 for	 support	and	 independent	groups	 separately	 following	
intervention.	
	
Two-way	 mixed	 ANOVA	 did	 not	 show	 any	 significant	 interactions	 between	
intervention	groups	over	time	for	IBD-F	score	(Table	26).	There	was	a	statistically	
significant	difference	in	mean	IBD-F	section	two	scores	at	the	different	time	points,	
F(1,56)	=	7.563,	p-0.008,	partial	η2	=	0.119.	The	mean	 IBD-F	 section	 two	scores	
decreased	 from	 26.1	 ±	 21.0	 at	 baseline	 to	 18.5	 ±	 21.0	 following	 the	 exercise	
intervention,	 a	 statistically	 significant	 difference	 of	 6.9	 points	 (95%	 CI	 1.869-
11.897).	 There	 was	 no	 statistically	 significant	 difference	 in	 mean	 IBD-F	 scores	
between	the	intervention	groups.		
	 	





















































































































Following	 the	 exercise	 intervention,	 HRQoL	 showed	 a	 significant	 increase	 in	 all	
aspects	of	the	IBDQ	except	the	social	sub-score	(Table	27).		
Table	27:	Change	in	mean	HRQoL	scores	(IBDQ)	following	the	exercise	intervention	for	whole	group.	
	 Before	 After	 Change	score	 p-value1		
Total	 176.1	±	25.3	 186.6	±	24.7		 10.5	(95%	CI	6.4	–	14.5)	 <0.0005	
Bowel	 55.1	±	9.6	 58.1	±8.7	 3.0	(95%	CI	1.3	–	4.7)	 0.001	
Emotion		 65.9	±	11.1	 70.2	±	11.1	 4.1	(95%	CI	2.2	–	6.1)	 <0.0005	
Systemic	 23.1	±	5.8		 26.0	±5.4	 2.6	(95%	CI	1.6	–	3.9)	 <0.0005	
Social		 32.0	±	3.7	 32.6	±	3.5	 0.6	(95%	CI	-0.05	–	1.1)		 0.073	
1	One-way	repeated	ANOVA	
	
Table	 28	 shows	 the	 change	 in	 HRQoL	 scores	 for	 both	 the	 support	 group	 and	
independent	 groups	 following	 the	 intervention.	 Two-way	mixed	ANOVA	did	 not	
show	any	statistically	significant	interactions	between	the	intervention	groups	and	





Table	 28:	 Change	 in	 mean	 HRQoL	 scores	 (IBDQ)	 for	 support	 and	 independent	 groups	 separately	
following	the	exercise	intervention.	









































































3.4.1.4 DEPRESSION AND ANXIETY  


















both	 the	 support	 and	 independent	 groups.	 There	was	 no	 significant	 interaction	
between	the	intervention	groups	and	time	on	depression	and	anxiety	scores.	The	
main	effect	of	time	showed	a	statistically	significant	difference	in	HADS	depression	
scores	 across	 time	 points,	 F(1,56)	 =	 5.592,	 p=0.022,	 partial	h2	 =0.091,	 in	 HADS	






























3.4.2 RELATIONSHIP BETWEEN COMPLIANCE AND CHANGES TO WELL-BEING  
Compliance	to	the	exercise	intervention	was	correlated	with	change	scores	for	well-
being	factors	(Table	30).	For	the	group	as	a	whole	and	the	independent	group,	no	






	 Total	 Support	(n=10)	 Independent	
(n=58)	
rs	 p-value		 rs	 p-value		 rs	 p-value		
MFI	 General	 -0.053	 0.692	 0.017	 0.962	 -0.100	 0.498	
Physical		 -0.120	 0.370	 -0.479	 0.161	 -0.065	 0.662	
Reduced	
Activity	
-0.219	 0.099	 -0.770	 0.009	 -0.093	 0.528	
Reduced	
Motivation	
-0.090	 0.502	 -0.117	 0.747	 -0.099	 0.501	
Mental		 -0.095	 0.477	 0.381	 0.267	 -0.251	 0.086	
IBD-F	 Section	One	 0.154	 0.250	 0.164	 0.651	 0.117	 0.230	
Section	Two		 -0.006	 0.966	 0.480	 0.160	 -0.097	 0.513		
IBDQ		 Bowel	 -0.152	 0.254	 -0.231	 0.521	 -0.157	 0.286	
Emotional	 -0.130	 0.330	 -0.462	 0.179	 -0.078	 0.600	
Systemic		 -0.042	 0.757	 -0.043	 0.907	 -0.097	 0.511	
Social		 -0.256	 0.052	 -0.249	 0.487	 -0.0271	 0.062	
Total		 -0.144	 0.285	 -0.021	 0.953	 -0.158	 0.288	
HADS	 Depression	 -0.062	 0.642	 -0.021	 0.953	 -0.089	 0.547	
























	 	 	 Walking		 Moderate	 Vigorous	 Total	
MFI	 General	 rs	 0.231	 -0.005	 -0.204	 -0.011	
p-value	 0.087	 0.970	 0.136	 0.934	
Physical		 rs	 0.259	 -0.260	 -0.064	 -0.004	
p-value	 0.054	 0.055	 0.645	 0.977	
Reduced	
Activity	
rs	 -0.040	 0.030	 -0.098	 -0.105	
p-value	 0.772	 0.829	 0.475	 0.441	
Reduced	
Motivation	
rs	 -0.005	 -0.081	 -0.273	 -0.150	
p-value	 0.970	 0.557	 0.044	 0.268	
Mental		 rs	 0.066	 -0.252	 -0.173	 -0.162	
p-value	 0.627	 0.064	 0.208	 0.234	
IBD-F	 Section	
One	
rs	 -0.060	 0.020	 -0.272	 -0.187	
p-value	 0.660	 0.887	 0.044	 0.167	
Section	
Two		
rs	 -0.067	 0.080	 -0.070	 0.024	
p-value	 0.504	 0.366	 0.609	 0.863	
IBDQ	 Bowel	 rs	 -0.091	 0.124	 0.253	 0.183	
p-value	 0.504	 0.366	 0.062	 0.176	
Emotional	 rs	 -0.214	 0.027	 0.189	 -0.078	
p-value	 0.113	 0.847	 0.166	 0.567	
Systemic	 rs		 0.004	 0.119	 0.234	 0.159	
p-value	 0.974	 0.389	 0.086	 0.243	
Social		 rs	 -0.065	 0.093	 -0.296	 -0.261	
p-value	 0.636	 0.502	 0.028	 0.052	
Total	 rs	 -0.183	 0.139	 0.226	 0.062	
p-value	 0.181	 0.317	 0.100	 0.653	
HADS	 Depression	 rs	 -0.264	 -0.001	 0.044	 -0.103	
p-value	 0.049	 0.995	 0.749	 0.451	
Anxiety	 rs	 0.000	 -0.074	 -0.119	 -0.051	
p-value	 0.998	 0.589	 0.385	 0.709	
	
	
An	 increase	 in	vigorous	physical	 activity	was	correlated	with	a	decrease	 in	MFI-
reduced	motivation,	rs(58)	=	-0.273,	P=0.044,	and	a	decrease	in	IBD-F	section	one	
was	 also	 correlated	 with	 an	 increase	 in	 vigorous	 physical	 activity	 (MET-
mins/week),	rs(58)	=	-0.272,	p=0.044.	Unexpectedly,	a	decrease	in	the	IBDQ-social	
sub-scale	scores	was	also	correlated	with	an	increase	in	vigorous	physical	activity,	










or	 vigorous	 physical	 activity	 were	 not	 correlated	 with	 any	 fatigue,	 HRQoL,	







	 Walking		 Moderate	 Vigorous	 Total	
MFI	 General	 rs	 0.363	 0.003	 0.226	 0.615	
p-value	 0.302	 0.993	 0.520	 0.058	
Physical		 rs	 -0.152	 -0.429	 0.379	 0.000	
p-value	 0.674	 0.216	 0.281	 1.000	
Reduced	
Activity	
rs	 -0.828	 -0.037	 0.089	 -0.755	
p-value	 0.003	 0.919	 0.807	 0.012	
Reduced	
Motivation	
rs	 -0.037	 0.028	 0.529	 0.320	
p-value	 0.919	 0.939	 0.116	 0.367	
Mental		 rs	 0.436	 0.210	 0.159	 0.767	
p-value	 0.208	 0.561	 0.661	 0.010	
IBD-F	 Section	
One	
rs	 -0.006	 0.432	 -0.383	 -0.105	
p-value	 0.986	 0.213	 0.274	 0.773	
Section	
Two		
rs	 0.394	 0.030	 0.013	 0.382	
p-value	 0.269	 0.933	 0.973	 0.276	
IBDQ	 Bowel	 rs	 -0.358	 0.463	 0.213	 -0.091	
p-value	 0.310	 0.177	 0.554	 0.803	
Emotional	 rs	 -0.337	 -0.444	 -0.254	 -0.693	
p-value	 0.340	 0.198	 0.479	 0.026	
Systemic	 rs	 -0.030	 -0.285	 -0.104	 -0.287	
p-value	 0.933	 0.424	 0.775	 0.422	
Social		 rs	 -0.403	 0.051	 -0.274	 -0.208	
p-value	 0.248	 0.889	 0.444	 0.565	
Total	 rs	 -0.236	 -0.244	 -0.176	 -0.503	
p-value	 0.511	 0.497	 0.627	 0.138	
HADS	 Depression	 rs	 0.128	 -0.628	 0.332	 0.147	
p-value	 0.724	 0.052	 0.348	 0.686	
Anxiety	 rs	 0.062	 -0.245	 0.128	 0.259	














being	 change	 scores	 for	 the	 independent	 group.	 Changes	 in	 vigorous	 physical	






	 Walking		 Moderate	 Vigorous	 Total	
MFI	 General	 rs	 -0.123	 0.399	 -0.116	 0.079	
p-value	 0.412	 0.006	 0.444	 0.598	
Physical		 rs	 -0.138	 0.142	 -0.192	 -0.097	
p-value	 0.356	 0.347	 0.202	 0.516	
Reduced	
Activity	
rs	 0.156	 0.082	 -0.276	 -0.095	
p-value	 0.296	 0.586	 0.063	 0.527	
Reduced	
Motivation	
rs	 -0.112	 0.252	 -0.110	 0.007	
p-value	 0.452	 0.091	 0.468	 0.961	
Mental		 rs	 -0.289	 0.245	 -0.126	 -0.117	
p-value	 0.049	 0.101	 0.405	 0.434	
IBD-F	 Section	
One	
rs	 -0.144	 0.338	 -0.150	 0.038	
p-value	 0.333	 0.022	 0.319	 0.799	
Section	
Two		
rs	 -0.183	 0.324	 -0.245	 -0.005	
p-value	 0.219	 0.028	 0.101	 0.976	
IBDQ	 Bowel	 rs	 0.134	 -0.175	 -0.069	 -0.082	
p-value	 0.368	 0.246	 0.651	 0.585	
Emotional	 rs	 0.214	 -0.214	 0.100	 -0.044	
p-value	 0.148	 0.154	 0.507	 0.767	
Systemic	 rs	 -0.029	 -0.272	 0.039	 -0.165	
p-value	 0.846	 0.068	 0.795	 0.269	
Social		 rs	 0.000	 0.011	 -0.125	 -0.178	
p-value	 0.998	 0.944	 0.409	 0.232	
Total	 rs	 0.181	 -0.240	 0.044	 -0.078	
p-value	 0.229	 0.113	 0.776	 0.607	
HADS	 Depression	 rs	 -0.222	 0.106	 -0.208	 -0.224	
p-value	 0.133	 0.485	 0.165	 0.131	
Anxiety	 rs	 -0.462	 0.008	 -0.200	 -0.266	






spent	walking,	rs(48)	=	 -0.289,	p=0.049.	Both	IBD-F	 section	one	and	 two	change	
scores	 showed	 a	 moderate	 positive	 correlation	 with	 moderate	 physical	 activity	
change	scores,	rs(48)	=	0.338	and	0.324	respectively,	p<0.05.	A	decrease	in	anxiety	
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is	 difficult	 to	 achieve	 (180).	 This	 study	 aimed	 to	 assess	 if	 a	 multidimensional	
approach	to	a	personalised	exercise	programme	in	patients	with	IBD	would	achieve	




The	 major	 findings	 of	 this	 study	 were:	 1)	 overall	 the	 compliance	 level	 to	 the	
personalised	programme	was	much	higher	than	compliance	levels	reported	in	the	
literature,	2)	the	exercise	intervention	resulted	in	improvements	in	all	aspects	of	
well-being,	 3)	 significantly	 more	 participants	 were	 in	 remission	 following	 the	
exercise	 intervention,	 and	 4)	 higher	 compliance	 did	 not	 result	 in	 greater	
improvement	in	well-being.		
	









Unexpectedly,	 almost	 four	 times	 as	 many	 participants	 chose	 to	 go	 into	 the	










showed	 a	 well-defined	 cohort	 of	 patients	 who	 matched	 both	 the	 general	 New	










each	 day	 and	 overall	 had	 a	 significantly	 higher	 attrition	 rate	 compared	 to	 the	
independent	group.	One	of	 the	possible	reasons	 for	 the	high	attrition	rate	 in	 the	
support	 group	may	 relate	 to	 motivation	 and	 their	 perceived	 expectations.	 This	
group	chose	to	participate	in	the	group	which	offered	extra	exercise	sessions	and	





women	who	dropped	out	of	 the	study	were	much	more	 likely	 to	have	very	high	






who	 remained	 in	 the	 study.	 Therefore,	 it	 could	 be	 hypothesised	 that	 those	
participants	who	were	lost	to	follow-up	already	felt	confident	in	exercising	and	had	




4.2 EXERCISE COMPLIANCE  
Compliance	to	the	unsupervised	exercise	intervention	was	significantly	higher	than	
expected.	 The	 overall	 compliance	 using	 intention	 to	 treat	 analysis	 was	 56%.	
However,	many	of	the	studies	mentioned	in	section	1.3.5.1	measured	compliance	
using	per-protocol	analysis	and	so	only	included	those	who	completed	the	study.	
Therefore,	 the	 compliance	 to	 the	 exercise	 intervention	 in	 this	 study	 using	 per-
protocol	 analysis	 is	 much	 higher	 (83.3%)	 and	 is	 higher	 than	 three	 of	 the	 four	
exercise	 interventions	 in	patients	with	 IBD	that	 listed	their	compliance	(98,	100,	
190).	 The	 fourth	 study	 had	 a	 compliance	 rate	 of	 100%	 but	 only	 required	





patients	 and	 the	majority	 of	 the	 supervised	 exercise	 programmes	 involving	 CRC	






of	 physical	 activity	 they	 enjoyed	 and	 this	 may	 have	 encouraged	 participants	 to	
maintain	 the	 exercise	 programme.	 This	 effect	was	 reported	 by	 Lewis	 et	 al.	who	
showed	 that	 physical	 activity	 enjoyment	 significantly	 predicted	 physical	 activity	
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participation	 at	 12	 months	 indicating	 that	 those	 who	 enjoyed	 participating	 in	
physical	activity	were	more	likely	to	maintain	a	physical	activity	programme	(170).	
Similarly,	 many	 participants	 in	 this	 study	 unknowingly	 chose	 to	 participate	 in	





setting	 and	 implementation	 intentions.	 These	 two	 tools	 may	 have	 allowed	
participants	to	begin	to	actively	remind	themselves	to	carry	out	their	exercise	plan	
they	 created	 without	 requiring	 reminders	 from	 the	 study	 co-ordinators.	 As	
mentioned	 by	 Gollwitzer	 et	 al.,	 using	 implementations	 intentions	 in	 this	 study	
would	have	allowed	participates	to	create	a	strategy	to	successfully	implement	the	
physical	 activity	 plan	 they	 had	 chosen	 (168).	Belanger-Gravel	 et	 al.,	 described	 a	
similar	 finding	 in	 their	 meta-analysis	 of	 implementation	 intentions	 in	 exercise	
interventions	(165).	The	researchers	reported	that	the	increase	in	physical	activity,	
and	the	benefits	associated	with	this,	continued	over	a	long	period	of	non-contact	
time	 in	 studies	 which	 employed	 implementation	 intentions	 and	 that	
“implementation	 intentions	 represented	 a	 low	 cost	 and	 easy-to-deliver	
intervention	 to	 favour	 long-term	 maintenance	 of	 changes	 in	 physical	 activity”	
(165).	 Similarly,	 the	 information	 provided	 on	 goal	 setting	 focused	 on	 setting	
realistic	 and	 achievable	 goals	 therefore	 ensuring	 that	 participants	 would	 not	
experience	 the	 discouragement	 that	 occurs	 when	 unrealistic	 goals	 are	 set	 for	
themselves	(174).	
When	comparing	compliance	to	the	intervention	between	the	support	group	and	
independent	group,	 a	 slight	difference	 in	 compliance	between	 the	 two	groups	 is	
apparent	 (73.3%	 vs	 85.5%	 respectively).	 The	 exact	 reason	 for	 this	 difference	 is	
unclear.	As	mentioned	previously,	 lower	 compliance	 to	 the	 study	 in	 the	 support	









capable	 of	 providing	 their	own	motivation	 to	participate	 in	 the	 programme	 and	
through	successfully	use	implementation	intentions	may	not	have	struggled	with	
complying	with	the	study.		
Published	data	suggests	 that	 long-term	adherence	to	exercise	 is	often	difficult	 to	
achieve	and	is	documented	to	rapidly	decrease	with	as	many	as	50%	of	individuals	
giving	 up	 on	 their	 exercise	 programme	 within	 the	 first	 six	 months	 (180).	 Not	
surprisingly	then,	compliance	to	the	exercise	intervention	in	this	study	was	seen	to	
decrease	 over	 time	 in	 both	 groups	with	 the	 support	 group	 experiencing	 a	more	
significant	 decrease	 than	 the	 independent	 group	 (Figure	 11).	 This	 decline	 was	
statistically	 significant	 illustrating	 that	 while	 compliance	 to	 the	 exercise	
programme	was	high	during	the	study,	 it	did	slowly	decrease	and	therefore	 it	 is	
likely	that	the	number	of	exercise	sessions	each	participant	continues	to	do	after	
the	completion	of	the	study	will	decrease	further.		
Interestingly,	 during	 analysis	 of	 compliance,	 no	 variables	 were	 predictive	 of	
compliance,	nor	were	there	any	significant	differences	in	compliance	between	the	




in	 this	 population	 of	 patients	 with	 IBD	 –	 especially	 if	 these	 factors	 can	 be	
manipulated.		
	
4.3 PHYSICAL ACTIVITY LEVELS 
At	 baseline,	 the	majority	 of	 participants	were	 in	 the	moderate	 physical	 activity	
category	 and	 over	 2/3	 of	 the	 participants	 met	 New	 Zealand	 physical	 activity	
guidelines.	 Compared	 to	 the	 general	 population	 in	 New	 Zealand,	 the	 United	
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Kingdom,	and	United	States,	participants	in	this	study	were	much	more	physically	
active	 (2,	3).	This	 level	of	physical	 activity	 contradicts	previous	 literature	which	
found	 that	 patients	with	 IBD	 often	 participate	 in	 less	 physical	 activity	 than	 the	
general	population	worldwide	(4,	5,	187).		
While	 the	 studies	 which	 have	 employed	 accelerometers	 to	 measure	 physical	
activity	have	found	that	patients	with	IBD	participate	in	less	physical	activity	(4,	5),	
studies	which	have	employed	questionnaires	 to	assess	physical	 activity	 levels	 in	










from	 the	 study	 (98).	While	 this	present	study	was	unable	 to	do	any	 comparison	
between	those	who	declined	to	participate	and	those	who	chose	to	participate	in	
the	 study	 it	 is	 likely	 that	 there	will	 be	 a	 significant	 difference	 between	 the	 two	
groups	in	terms	of	motivation.		
	




high	 physical	 activity	 category;	 7%	of	 the	whole	 group	met	 the	 criteria	 for	 this	
category	at	baseline	but	almost	28%	met	 the	criteria	 following	 the	 intervention.	
This	is	an	important	finding	as	it	shows	how	effective	the	personalised	programme	
can	be.	Because	of	 the	 lack	of	 instruction	around	duration	and	type,	participants	
could	have	chosen	to	remain	at	their	current	level	of	physical	activity	rather	than	
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study.	 It	 is	 unclear	 exactly	 why	 their	 study	 was	 not	 successful	 in	 encouraging	










4.3.2 ATTITUDES AND PREFERENCES TO EXERCISE  
The	most	 preferred	 form	 of	 exercise	 for	 the	 cohort	 was	 walking,	 aligning	 with	
previous	 research	 (58,	 188,	 214).	 Further	 to	 this,	 the	 results	 also	 indicated	 a	
preference	towards	low	impact	exercise	types	 for	patients	who	have	IBD	as	high	
impact	exercise	 such	as	running	or	playing	sports	represented	 less	 than	10%	of	
responses	of	preferred	exercise.	While	it	is	common	for	the	general	population	to	










with	other	 research	which	 indicated	 that	 IBD	affects	perception	around	exercise	
capacity	 and	 fitness	 (58,	 188).	 Common	 reasons	 for	 the	 limitation	 in	 exercise	
mentioned	in	previous	studies	–	fatigue,	abdominal	pain,	trouble	controlling	bowels	
–	were	prominent	for	the	study	participants	(58,	188).	At	the	end	of	the	study,	not	
having	 enough	 time	 and	 fatigue	 were	 the	 two	 main	 barriers	 still	 present.	 This	
illustrates	 that	 while	 the	 exercise	 programme	 may	 have	 decreased	 fatigue	
objectively,	participants	still	felt	that	fatigue	was	significantly	affecting	their	ability	
to	partake	in	exercise.		
Unexpectedly,	 this	 study	 demonstrated	 a	 clear	 dissociation	 between	 perceived	
barriers	and	ability	to	exercise.	At	baseline,	there	was	a	high	proportion	of	patients	
with	active	disease	who	reported	that	their	IBD	had	limited	their	ability	to	exercise	









4.4  WELL-BEING 
Overall,	 participants	 in	 this	 present	 study	 had	 a	 high	 HRQoL	 at	 baseline.	 This	
contrasts	previous	literature	where	HRQoL	is	often	significantly	reduced	in	patients	
with	 IBD,	 even	 those	 in	 remission	 (86,	 87).	 It	 is	 known	 in	 the	 literature,	 and	
reproduced	in	this	study,	that	HRQoL	is	inversely	related	to	disease	activity	(82,	89).	
This	may	 in	 part	 explain	why	 participants	 in	 this	 study	had	 higher	HRQoL	 than	
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expected	as	the	majority	of	participants	had	inactive	disease.	Other	key	factors	that	
were	 consistently	 associated	with	 reduced	HRQoL	 in	 this	 study	 included	 female	
gender	and	having	had	previous	surgery.	An	unexpected	finding	of	this	study	was	
that	having	had	previous	surgery	was	significantly	correlated	with	reduced	HRQoL	
as	 this	 is	 the	 opposite	 of	 previously	 published	 literature.	 In	 a	 recent	 systematic	
review	 investigating	 changes	 to	 HRQoL	 following	 surgery	 in	 patients	 with	 CD,	
HRQoL	was	found	to	significantly	improve	following	surgery	in	both	the	short-term	
and	 long-term	 (215).	 Therefore,	 it	 is	 unclear	why	 in	 this	 study	 HRQoL	was	 not	
higher	for	those	who	had	surgery	compared	to	those	who	had	not.		
In	this	study,	participants	had	a	high	level	of	fatigue	as	seen	using	both	the	MFI	and	











experienced	high	 levels	of	 fatigue	but	were	 in	 remission.	This	 study	adds	 to	 the	
literature	around	fatigue	levels	in	patients	with	IBD	and	further	illustrates	the	need	
for	 exploration	 of	 other	modifiable	 factors	 in	 order	 to	 improve	 patients	 fatigue	
levels	while	in	remission.		
While	 low	 physical	 activity	 has	 been	 correlated	 with	 increased	 fatigue	 in	 the	
literature	 (58,	 62),	 only	 one	 aspect	 of	 the	MFI	 showed	 a	 statistically	 significant	
difference	across	physical	activity	levels	in	this	present	study	at	baseline.	However,	






In	 this	 present	 study,	 participants	 had	 higher	 levels	 of	 anxiety	 compared	 with	
depression,	 with	 almost	 30%	 of	 participants	 having	 a	 borderline	 high	 score	 or	
greater	for	anxiety.	While	these	figures	appear	high,	they	are	slightly	lower	than	the	














physical	 activity	 category	 showed	higher	 levels	 of	 anxiety	 than	 those	 in	 the	 low	
physical	activity	category	at	baseline.	While	the	unusual	relationship	was	seen	at	
baseline,	 a	 drastic	 improvement	 in	 anxiety	 scores	 following	 the	 exercise	
intervention	was	seen	with	less	than	10%	of	participants	having	a	borderline	high	
anxiety	 score	at	 the	end	of	 the	exercise	 intervention	compared	 to	 the	beginning	
where	almost	30%	of	participants	had	a	borderline	high	anxiety	score.		
Depression	 levels	 also	 saw	 a	 significant	 decrease	 following	 the	 exercise	
intervention	 and	 a	 change	 in	 physical	 activity	 scores	 was	 correlated	 with	 an	
improvement	 in	 depression	 levels.	 This	 significant	 change	 in	 depression	 and	
anxiety	 levels	 following	 the	 exercise	 intervention	 adds	 further	 evidence	 that	 an	





well	 as	 an	 improvement	 in	HRQoL.	 This	 contrasts	 a	 similar	 study	 conducted	 by	






well-being	 (98-100).	 However,	 this	 does	 not	 detract	 from	 the	 significant	
improvement	in	well-being	that	patients	experienced	in	this	study	and	illustrates	
how	 effective	 a	 pragmatic,	 multidimensional	 exercise	 programme	 given	 to	
participants	can	be	at	improving	their	well-being.		
Improvements	 in	 well-being	 (fatigue,	 HRQoL,	 depression,	 and	 anxiety)	 were	
significantly	 correlated	 with	 a	 corresponding	 increase	 in	 physical	 activity.	 This	
correlation	may	highlight	a	potential	mechanism	for	the	noticeable	improvement	in	
well-being.	It	has	been	described	by	O’Sullivan	et	al.	that	habitual	physical	activity	
modulates	 the	 immune	 system	 and	 leads	 to	 a	 suppression	 of	 basal	 pro-
inflammatory	 cytokines	 (145).	 Secondly,	 high	 levels	 of	 inflammation	 reduce	
signalling	in	the	brain	and	create	a	‘sickness	behaviour’	involving	increased	fatigue	
levels,	reduced	activity,	mood	changes,	and	reduced	appetite	(75).	Therefore,	in	the	
participants	 in	 this	study,	 it	 is	possible	 that	 the	 increase	 in	physical	activity	may	
have	 led	 to	 a	 decrease	 in	 inflammation,	 in	 turn	 resulting	 in	 less	 inflammation	






UC	where	 the	mean	 score	 of	 the	 SCCAI	 following	 the	 exercise	 intervention	was	
below	 the	 score	 given	 to	 define	 remission.	 Additionally,	 the	 proportion	 of	
participants	with	disease	in	remission	increased	significantly	flowing	the	exercise	
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intervention.	 This	 finding	 further	 adds	 to	 the	 literature	 that	 increasing	 physical	
activity	can	improve	disease	activity	in	patients	with	IBD	(98,	99,	151).	Further	to	
this,	 the	 considerable	 number	 of	 participants	 whose	 disease	 activity	 changed	
following	the	exercise	intervention	means	that	the	increase	in	physical	activity	was	
likely	 exerting	 a	 positive	 effect	 on	 disease	 activity	 and	 therefore	 this	may	 have	
contributed	to	participants	improving	their	well-being.		
	
4.5 RELATIONSHIP BETWEEN COMPLIANCE AND WELL-BEING 
The	 secondary	 aim	 of	 this	 study	was	 to	 investigate	 if	 higher	 compliance	would	
achieve	 a	 greater	 improvement	 in	 well-being	 compared	 to	 those	 with	 lower	
compliance	 to	 the	 exercise	 programme.	 While	 there	 was	 no	 relationship	 seen	
between	compliance	and	well-being	with	the	group	as	a	whole	as	well	as	with	the	








4.6 LIMITATIONS  
As	with	 any	 study,	 this	 present	 study	 has	 its	 limitations.	 The	 first	 is	 the	 use	 of	
subjective	measures	throughout	the	study.	This	is	a	limitation	which	is	experienced	
with	many	studies	measuring	subjective	topics	such	as	fatigue,	HRQoL,	depression,	
or	 anxiety.	 Because	 each	 person	 interprets	 their	 well-being	 based	 on	 personal	
experiences,	each	is	likely	to	report	their	well-being	in	a	different	way	to	others	in	
the	study	due	to	different	experiences.	This	may	have	impacted	the	results	obtained	




study,	 a	 subjective	 measure.	 It	 is	 likely	 that	 each	 participant	 used	 their	 own	
interpretation	 of	what	 constituted	 moderate	 or	 vigorous	 physical	 activity,	 even	
when	further	information	was	provided,	to	answer	the	IPAQ.	This	may	have	created	
a	difference	between	the	perceived	exercise	a	participant	has	done	and	the	actual	
level	 of	 physical	 activity	 completed	 as	 assessed	 by	 the	 IPAQ.	 Therefore,	 it	 was	




assumption	 was	 made	 around	 effect	 size	 of	 the	 intervention	 and	 therefore	 no	
sample	size	calculations	for	the	study	were	made.	The	relatively	small	sample	size	








study	was	 a	 voluntary	 study	 looking	 at	 a	personalised	 exercise	 programme	 it	 is	
entirely	 possible	 that	 those	who	 chose	 to	 participate	 in	 the	 study	were	 a	 highly	
motivated	 group	 of	 individuals	who	were	 already	 participating	 in	 high	 levels	of	
physical	activity	and	therefore	are	significantly	different	from	those	who	chose	not	
to	participate	in	the	study.		
The	 final	 limitation	 of	 the	 study	 relates	 to	 the	 ability	 to	 meaningfully	 contrast	
between	the	two	groups	of	the	study.	This	study	was	not	a	randomised	control	trial;	
therefore,	 it	was	not	 the	aim	of	 this	study	to	statistically	compare	compliance	or	
wellbeing	outcomes	between	the	two	groups.	This	was	chosen	to	stimulate	a	real-
world	model	where	people	would	have	the	choice	to	have	additional	support	when	
beginning	 a	 new	 exercise	 programme.	 As	 such	 there	 was	 no	 opportunity	 to	
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randomise,	making	 comparisons	 between	 groups	 impractical.	 In	 further	 studies,	
randomisation	would	be	beneficial	 to	 improve	on	this	limitation.	Further	to	 this,	
there	is	no	control	group	in	this	study	making	comparisons	in	changes	to	well-being	
between	 groups	 difficult.	 	 	 However,	 it	 is	 important	 to	 note	 that	 throughout	 the	
thesis	 statistical	 comparisons	 have	 been	made	 between	 the	 groups	 in	 order	 to	
illustrate	 to	 the	 reader	 important	 differences,	 or	 lack	 of	 differences,	 that	 were	
apparent	between	the	groups.	
	
4.7 IMPLICATIONS  
The	pilot	 study	described	 in	 this	 thesis	offers	many	positive	 findings	which	may	
have	implications	on	future	health	practices.	The	first	is	that	this	study	reinforces	
the	knowledge	 that	physical	 activity	offers	numerous	health	benefits	 to	patients	
with	 IBD	 including	 reducing	 fatigue,	 depression,	 and	 anxiety	 levels,	 as	 well	 as	
improving	 HRQoL.	 Secondly,	 this	 study	 illustrates	 how	 effective	 a	 pragmatic,	
multidimensional	approach	can	be	at	 improving	physical	activity	participation	 in	




4.8 AVENUES FOR FUTURE RESEARCH 
From	this	current	study,	a	number	of	avenues	for	future	research	have	been	created	
in	which	answers	may	be	found	to	questions	raised:	
1. It	 is	 still	 unclear	 which	 method	 of	 intervention	 (pragmatic	 versus	 set	
programme)	results	 in	higher	compliance	and	changes	to	well-being.	This	
study	 was	 unique	 in	 its	 use	 of	 a	 pragmatic	 approach	 to	 an	 exercise	
programme	 which	 contrasts	 previous	 research	 which	 focused	 on	 set	
exercise	programmes.	This	raises	the	question	of	which	approach	is	superior	





from	 investigating	 which	 of	 these	 elements	 works	 best	 at	 improving	











a	 personalised	 exercise	 programme	would	 achieve	 high	 levels	 of	 compliance	 in	
patients	with	IBD.	With	physical	activity	participation	at	an	all-time	low	world-wide	










This	 study	 intended	 to	 create	 one	 such	 tool	 for	 doctors	 to	 use	 -	 a	 personalised	
exercise	 booklet.	 This	 booklet	 allowed	 participants	 to	 create	 a	 physical	 activity	
programme	 that	 they	would	 enjoy	 and	maintain	with	 throughout	 the	 study.	 By	
providing	participants	with	unique	elements	in	the	programme	such	as	education	
on	 goal	 setting,	 personalisation,	 barrier	 planning,	 and	 a	 reward	 system,	 it	 was	






The	 secondary	 aim	 of	 the	 study	 was	 to	 investigate	 the	 relationship	 between	
compliance	to	the	physical	activity	levels	and	changes	to	patients’	well-being.	While	
no	 significant	 relationship	 was	 seen	 between	 compliance	 levels	 and	 changes	 in	
well-being	in	this	study,	participants	who	completed	the	study	noticeably	improved	
their	 HRQoL	 and	 decreased	 their	 levels	 of	 fatigue,	 depression,	 and	 anxiety.	
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Importantly,	 following	 the	 conclusion	 of	 the	 exercise	 programme	 there	 was	 a	
significant	 increase	 in	 the	 proportion	 of	 participants	 whose	 disease	 was	 in	
remission.		


































































































































































































































































































































































































































































































































































































































































































































































APPENDIX I – INFORMATION SHEET AND CONSENT FORM 
Department of Medicine  
PARTICIPANT INFORMATION SHEET 
 
A Unique Approach to Exercising – Does Sticking 




You are invited to take part in a study looking at a personalised exercise programme 
and if a unique approach will help you stick with it. If you stick with the programme it is 
hoped that your fatigue, quality of life and disease activity will improve. Whether you 
take part is your choice. If you don’t want to take part, you don’t have to give a reason 
and it won’t affect the care you receive. If you do want to take part now, but change 
your mind later, you can pull out of the study at any time.  
 
This Participant Information Sheet will help you decide if you would like to take part. It 
sets out why we are doing the study, what your participation will involve, what the 
benefits and risks to you might be, and what would happen after the study ends. We 
will go through this information with you and answer any questions you may have. You 
do not have to decide today whether you will participate in this study. Before you decide 
you may want to talk about the study with other people, such as family, whānau, 
friends, or healthcare providers. Feel free to do this. 
 
If you agree to take part in this study, you will be asked to sign the Consent Form on the 
last page of this document. You will be given a copy of both the Participant Information 
Sheet and the Consent Form to keep. 
 
This document is 8 pages long, including the consent form. Please make sure you have 




WHAT IS THE PURPOSE OF THE STUDY? 
Research has shown that exercise improves fatigue and quality of life. It has also been 
shown to maintain remission for longer in patients with Inflammatory Bowel Disease 
(IBD). It can be difficult to do the amount of exercise that you should be doing to achieve 
this. The purpose of this study is to look at if taking a unique approach to exercising will 
help you stick to the programme. It is also hoped that it will improve your fatigue and 
quality of life over time. The exercise programme is unique and has not been studied 
before so the results are unknown. It is hoped that you will experience improvements 
in your disease activity, quality of life and fatigue but it is not guaranteed. 
 
The study also aims to see if the exercise booklet contains enough information for you 
to exercise successfully.  
This project is being led by a student, Miss Georgina Fagan, as part of the requirements 
for the Bachelor of Medical Science with Honours degree.  
 
What Type of Participants are being sought? 
For this study, we are looking for people with inflammatory bowel disease. The study 
will run for four months. If you have other health issues you may be able to still join. 
We will make sure that our study has no effect on treatment you might be receiving.  
 
You can join this study if you have been diagnosed with IBD. 
 







If you are not sure about if you can join, feel free to contact us. We are aiming at having 
100-150 people in the study.  
 
What will Participants be Asked to Do? 
 
After agreeing to take part, you will be asked to give a small amount of blood, 2 stool 
samples – one being a used piece of toilet paper – and a urine sample. You will also be 
asked some questions relating to your fatigue, your quality of life and how active your 
IBD is. Your blood samples will be examined for inflammation & iron levels to see if 
there is an obvious reason for your fatigue. Your stool samples will be used to look for 
inflammation and the types of bacteria in your gut.  
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If you meet the criteria you can choose to go into one of two groups: 
• Group One: One month of exercising in a group with a trainer then three months 
of exercising independently using the exercise programme planner.  
• Group Two: Four months of exercising independently using the exercise 
programme planner. 
 
The exercise programme planner will have information on how to begin exercising and 
on how to meet your goals. You will also receive a Goal Chart and a pedometer. After 
one month, you will be asked to complete a survey on your fatigue.  
At the end of the four months, you will be asked to re-do the questionnaires you did at 
the start of the study. You will also need to have the blood test, stool and urine sample 
done again. After 6 & 12 months, you will be contacted again by post or email to 
complete the final questionnaires around your fatigue and exercise participation.  
 
The study will involve two clinic visits, one at the start of the study and one at the end 
of the 4 months. These visits will be used to fill out the questionnaires and receive all 
the study material you need. You will also need to make a trip to a Southern Community 
laboratory to have your blood test taken and to supply your stool sample.  
For each study visit you will receive a $10 fuel voucher a reimbursement for your time.  
 
Your medical records will be accessed for the project. Remember, you can decide not 
to take part in the study at any time without any disadvantage. 
 
WHAT ARE THE POSSIBLE RISKS OF THIS STUDY? 
When blood is taken from your arm, you may feel some discomfort and bruising where 
the needle is inserted. These usually resolve quickly and can be reduced by applying 
firm pressure over the site.  
There is a risk that you may experience some discomfort when exercising. However, this 
is normal when beginning to exercise. If this concerns you or doesn’t go away contact 
your regular doctor or someone from this study for help. 
 
You will be informed if there is any new information about adverse or beneficial events 
related to the study that may be revealed during the study.  
WHAT IF SOMETHING GOES WRONG?  
If you were injured in this study, which is unlikely, you would be eligible to apply for 
compensation from ACC just as you would be if you were injured in an accident at work 
or at home. This does not mean that your claim will automatically be accepted. You will 
have to lodge a claim with ACC, which may take some time to assess. If your claim is 
accepted, you will receive funding to assist in your recovery.  
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If you have private health or life insurance, you may wish to check with your insurer 
that taking part in this study won’t affect your cover 
 
CONFIDENTIALITY 
Once you have agreed to take part in this study, all personal information will remain 
confidential. It will only be able to be seen by the senior research team. The forms you 
complete during the study will identify you by number and only the principal 
investigator will be able to match your number to your name.  
The results of the project may be published. This will be available in the University of 
Otago Library (Dunedin, New Zealand) and every attempt will be made to preserve your 
anonymity. 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
All your personal information will be removed from the records of the study. The 
records will be placed in a secure place and kept for up to 10 years. The data from the 
study will be securely stored so that only those mentioned below will be able to access 
to it.  
Your blood test and one stool sample will be sent to the Southern Community 
laboratories to be tested then will be disposed of.  
Your other stool sample and urine sample will be frozen and then sent overseas to a 
laboratory in London, Ontario, Canada for testing. After testing it will also be disposed 
of.  
 
If you decided to withdraw from the study, all data collected from you up to that point 
will remain in the study unless otherwise specified. Once the study is finished you will 
be unable to withdraw your data. All of your data will be anonymous.  
 
Results from the study will be made available as soon as possible. If you wish, the 
research team will make themselves available to explain the findings to you.  
 
WHO SHOULD I CONTACT FOR MORE INFORMATION? 
If you have any questions about the project, please contact either –  
 
 Georgina Fagan Dr Hamish Osborne  
Phone: 021 130 7578  
Email: Exercise.dunedin@gmail.com Hamish.osborne@otago.ac.nz 
 
 
If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
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Phone:  0800 555 050 
Fax:           0800 2 SUPPORT (0800 2787 7678) 
Email:         advocacy@hdc.org.nz 
  
For Maori health support: 
If you require Māori cultural support talk to your whānau in the first instance. 
To ensure ongoing cultural safety the Maori Research Review Committee of the 
University of Otago and Southern District Health Board encourage those who identify 
themselves as Maori and who are participating in health research or clinical trials to 
seek cultural support and advice from either Mo Wai Te Ora – Maori Health Services or 
their own Kaumatua or Whaea 
 
 
You can also contact the health and disability ethics committee (HDEC) that approved 
this study on: 
      Phone:       0800 4 ETHICS 
      Email:       hdecs@moh.govt.nz 
 
Alternatively, you can contact the Health and Disability Commissioner on: 
      Phone: 0800 11 22 33 
      Email: hdc@moh.govt.nz 
 
Any issues you raise will be treated in confidence and investigated and you will be 
informed of the outcome. 





Department of Medicine 
CONSENT FORM: 
 
Please tick to indicate you consent to the following: 
 
I have read, or have had read to me in my first language, the 
Information Sheet concerning this project and understand what it is 
about. 
  
I have been given sufficient time to consider whether to participate in 
this study. 
  
I have had the opportunity to use legal representation, whānau/family 
support or a friend to help me ask questions and understand the study. 
  
I am satisfied with the answers I have been given regarding the study 
and I have a copy of this consent form and information sheet. 
  
I understand that taking part in this study is voluntary (my choice) and 
that I may withdraw from the study at any time without this affecting 
my medical care. 
  
I consent to the research staff collecting and processing my 
information, including information about my health.  
  
If I decide to withdraw from this study, I agree that the information 
collected about me up to the point when I withdraw may continue to 
be processed. 
¨ Yes ¨ No 
I consent to my GP or current provider being informed about my 
participation in the study and of any significant abnormal results 
obtained during the study. 
¨ Yes ¨ No 
I understand the nature and size of the risks of discomfort or harm 
which are explained in the information sheet.  
  
I consent for my samples being destroyed at the end of the study.   
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I wish to have my samples disposed of with appropriate karakia at the 
end of the study. I understand that my samples sent to Canada for 
testing cannot be disposed of with appropriate karakia. 
¨ Yes ¨ No 
I consent to having my stool and urine samples sent overseas to be 
analysed.  
  
I understand that my participation in this study is confidential and that 
no material that could identify me personally, will be used in any 
reports on this study.  
  
I understand the compensation provisions in case of injury during the 
study.  
  
I know who to contact if I have any questions about the study in 
general. 
  
I understand my responsibilities as a study participant.   
I wish to receive a summary of the results from the study.  ¨ Yes ¨ No 
 
 
Declaration by participant: 
I agree to take part in this project. 
 
 
...................................................................................  ............................... 






Declaration by member of the research team: 
I have given a verbal explanation of the research project to the participant and have 
answered the participant’s question about it.  




.............................................................................   ............................... 









































































APPENDIX IV – PHYSICAL ACTIVITY SURVEY AND IPAQ 
Current	Physical	Activity	Survey:	
This	 questionnaire	 is	 designed	 to	 gather	 information	 about	 your	 activity	 preferences,	
current	level	of	physical	activity	and	barriers	to	exercising.		
Instructions:	 	
In	 the	 table	below	please	 fill	 in	 an	additional	 three	 activities	 or	 exercise	 types	 that	 you	
would	enjoy	doing	for	most	of	the	days	in	a	week.		






















































































¨	Fatigue		 	 	 	 	 ¨	Muscle	Weakness	
¨	Joint	Pain	 		 ¨	Bowel	incontinence	
¨	Abdominal	Pain	 	 	 	 ¨	Other:___________________	
¨	Embarrassment	relating	to	symptoms	
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APPENDIX VIII – INFLAMMATORY BOWEL DISEASE FATIGUE SELF-
ASSESSMENT SCALE (IBD-F) 
Section	One	–	Fatigue	Assessment	Scale:		











0	 1	 2	 3	 4	
2. What	was	your	HIGHEST	fatigue	level	in	the	past	two	weeks?	
0	 1	 2	 3	 4	
3. What	was	your	LOWEST	fatigue	level	in	the	past	two	weeks?	
0	 1	 2	 3	 4	
4. What	was	your	AVERAGE	fatigue	level	in	the	past	two	weeks		




















0	 1	 2	 3	 4	
2. Fatigue	has	stopped	me	from	going	out	to	social	events		
0	 1	 2	 3	 4	
3. I	was	not	able	to	go	to	work	or	college	because	of	fatigue		
0	 1	 2	 3	 4	 N/A	
4. My	performance	at	work	or	education	was	affected	by	fatigue		
0	 1	 2	 3	 4	 N/A	
5. I	had	problems	concentrating	because	of	fatigue		
0	 1	 2	 3	 4	
6. I	had	difficulty	motivating	myself	because	of	fatigue		
0	 1	 2	 3	 4	
7. I	could	not	wash	and	dress	myself	because	of	fatigue		
0	 1	 2	 3	 4	
8. I	had	difficulty	walking	because	of	fatigue		
0	 1	 2	 3	 4	
9. I	was	unable	to	drive	as	much	as	I	needed	because	of	fatigue	
0	 1	 2	 3	 4	 N/A	
10. I	was	not	able	to	do	as	much	physical	exercise	as	I	wanted	to	because	of	fatigue		




0	 1	 2	 3	 4	
12. 	My	emotional	relationship	with	my	partner	was	affected	by	fatigue		
0	 1	 2	 3	 4	 N/A	
13. My	sexual	relationship	with	my	partner	was	affected	by	fatigue		
0	 1	 2	 3	 4	 N/A	
14. My	relationship	with	my	children	was	affected	by	fatigue		
0	 1	 2	 3	 4	 N/A	
15. I	was	low	in	mood	because	of	fatigue		
0	 1	 2	 3	 4	
16. I	felt	isolated	because	of	fatigue		
0	 1	 2	 3	 4	
17. My	memory	was	affected	by	fatigue		
0	 1	 2	 3	 4	
18. I	made	mistakes	because	of	fatigue		
0	 1	 2	 3	 4	
19. Fatigue	made	me	irritable		
0	 1	 2	 3	 4	
20. Fatigue	made	me	frustrated	
0	 1	 2	 3	 4	
21. I	got	words	mixed	up	because	of	fatigue		
0	 1	 2	 3	 4	
22. 	Fatigue	stopped	me	enjoying	my	life		
0	 1	 2	 3	 4	
23. Fatigue	stopped	me	from	having	a	fulfilling	life		
0	 1	 2	 3	 4	
24. My	self-esteem	was	affected	by	fatigue		




0	 1	 2	 3	 4	
26. Fatigue	made	me	feel	unhappy		
0	 1	 2	 3	 4	
27. 	I	had	difficulties	sleeping	at	night	because	of	fatigue		
0	 1	 2	 3	 4	
28. Fatigue	affected	my	ability	to	do	all	my	normal	household	activities		
0	 1	 2	 3	 4	
29. I	had	to	ask	others	for	help	because	of	my	fatigue		
0	 1	 2	 3	 4	
30. Quality	of	my	life	was	affected	by	fatigue		
































1	 I	feel	fit.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
2	 Physically,	 I	 feel	 only	 able	 to	 do	 a	
little.		
Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
3	 I	feel	very	active	 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
4	 I	feel	like	doing	all	sorts	of	things.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
5	 I	feel	tired.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
6	 I	think	I	do	a	lot	in	a	day.	 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
7	 When	 I	 am	 doing	 something,	 I	 can	
keep	my	thoughts	on	it.	
Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
8	 Physically,	I	can	take	on	a	lot.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
9	 I	dread	having	to	do	things.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
10	 I	think	I	do	very	little	in	a	day.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
11	 I	can	concentrate	well.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
12	 I	am	rested.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
13	 It	takes	a	lot	of	effort	to	concentrate	
on	things.		
Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
14	 Physically,	 I	 feel	 I	 am	 in	 bad	
condition.		
Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
15	 I	have	a	lot	of	plans.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
16	 I	tire	easily.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
17	 I	get	little	done.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
18	 I	don’t	feel	like	doing	anything.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
19	 My	thoughts	easily	wander.		 Yes,	that	is	true	 ¨	1	 ¨	2	 ¨	3	 ¨	4	 ¨	5	 No,	that	is	not	true	
20	 Physically,	 I	 feel	 I	 am	 in	 excellent	
condition.	





























































APPENDIX XII – CORRELATIONS BETWEEN BASELINE WELL-BEING AND DEMOGRAPHIC DATA FOR THE WHOLE GROUP 
Supplementary	Table	1:	Correlation	coefficients	between	baseline	fatigue	scores	(IBD-F	and	MFI)	and	continuous	demographic	variables,	whole	group.	




















-0.144	 0.128	 0.039	 0.456	 0.376	 -0.117	 0.070		 -0.125	 -0.107	 0.027	 0.111	 -0.178	





-0.280	 0.192	 -0.137	 0.431	 0.379	 -0.77	 -0.013	 0.012	 -0.090	 0.088	 0.038	 0.004	
p-value	 0.006	 0.09	 0.221	 0.003	 0.023	 0.492	 0.907	 0.914	 0.429	 0.476	 .0750	 0.977	
MFI	 General	 Correlation	
coefficient	
-0.269	 0.170	 0.016	 0.285	 0.271	 -0.065	 -0.037	 -0.135	 -0.191	 -0.121	 0.013	 -0.236	
p-value	 0.014	 0.132	 0.887	 0.058	 0.109	 0.565	 0.739	 -0.225	 0.087	 0.320	 0.911	 0.046	
Physical	 Correlation	
coefficient	
-0.320	 0.156	 0.037	 0.435	 0.413	 -0.165	 -0.134	 -0.266	 -0.292	 0.065	 0.113	 -0.130	





0.021	 0.053	 0.095	 0.173	 0.414	 -0.126	 -0.061	 -0.225	 -0.247	 0.070	 0.086	 -0.156	





-0.064	 0.190	 0.026	 0.139	 0.334	 -0.108	 -0.171	 0.141	 0.313	 0.102	 0.073	 -0.335	
p-value	 0.565	 0.091	 0.817	 0.361	 0.047	 0.336	 0.124	 0.205	 0.004	 0.405	 0.531	 0.004	
Mental	 Correlation	
coefficient	
-0.247	 -0.046	 -0.026	 0.256	 0.357	 -0.052	 0.01	 0.079	 -0.009	 -0.101	 -0.185	 -0.177	
























IBD-F	 Section	one	 Mean	 7.5/9.2	 10.2/6.9	 8.6/8.4	 9.7/7.8	 8.3/8.5	 8.6/7.8	 8.9/8.2	
p-value	 0.035	 <0.0005	 0.736	 0.014	 0.927	 0.462	 0.657	
Section	two	 Mean	 23.5/29.8	 35.0/19.6	 28.0/26.5	 32.0/24.3	 31.5/25.1	 27.6/24.6	 33.3/25.9	
p-value	 0.175	 0.002	 0.855	 0.271	 0.357	 0.400	 0.096	
MFI	 General	 Mean	 12.2/14.7	 14.7/12.6	 13.3/13.7	 14.3/13.3	 13.4/13.7	 13.9/12.3	 13.1/13.7	
p-value	 0.004	 0.033	 0.694	 0.282	 0.740	 0.124	 0.426	
Physical	 Mean	 11.3/13.1	 13.9/10.8	 12.6/12.1	 12.7/12.0	 12.3/12.3	 13.5/11.1	 13.5/11.9	
p-value	 0.026	 0.001	 0.800	 0.475	 0.951	 0.215	 0.123	
Reduced	
Activity	
Mean	 9.4/10.6	 11.0/9.2	 10.6/9.8	 10.6/9.7	 10.0/10.0	 10.2/9.1	 10.9/9.7	
p-value	 0.127	 0.030	 0.393	 0.398	 0.967	 0.364	 0.138	
Reduced	
Motivation	
Mean	 9.5/10.7	 11.1/9.3	 10.0/10.2	 10.4/10.2	 11.0/9.8	 10.2/9.9	 10.3/10.1	
p-value	 0.147	 0.028	 0.537	 0,786	 0.234	 0.717	 0.595	
Mental	 Mean	 9.2/10.6	 10.9/9.1	 11.2/9.5	 10.5/9.8	 10.1/9.9	 10.0/9.9	 9.8/10.0	

























0.1472	 -0.100	 0.091	 -0.656	 -0.675	 0.032	 -0.095	 0.069	 0.049	 -0.104	 -0.093	 0.262	





0.1362	 -0.040	 0.073	 -0.661	 -0.662	 -0.033	 -0.138	 0.059	 0.003	 -0.050	 -0.153	 0.362	





0.1012	 -0.038	 0.019	 -0.426	 -0.497	 -0.017	 -0.087	 -0.055	 -0.020	 -0.040	 0.032	 0.153	





0.1741	 -0.282	 0.128	 -0.563	 -0.612	 0.108	 -0.044	 0.145	 0.140	 -0.144	 -0.098	 0.170	





0.0682	 -0.089	 0.165	 -0.544	 -0.643	 0.087	 0.010	 0.029	 0.039	 -0.306	 -0.258	 0.335	
p-value	 0.545	 0.434	 0.141	 <0.0005	 <0.0005	 0.440	 0.929	 0.800	 0.733	 0.011	 0.027	 0.004	




















Total	score		 Mean	 184.3/168.8	 161.8/188.9	 174.5/176.4	 163.8/181.7	 167.0/179.4	 175/4/177.6	 171.9/177.1	
p-value	 0.003	 <0.0005	 0.757	 0.003	 0.145	 0.427	 0.308	
Bowel		
sub-score	
Mean	 59.6/51.9	 50.8/59.7	 56.0/55.2	 50.9/57.7	 53.0/56.4	 55.3/56.1	 54.1/55.8	
p-value	 <0.0005	 <0.0005	 0.512	 0.001	 0.138	 0.479	 0.295	
Emotional		
sub-score		
Mean	 67.0/64.1	 60.7/70.0	 64.8/65.7	 61.0/67.4	 62.4/66.6	 65.5/64.9	 63.9/65.9	
p-value	 0.525	 <0.0005	 0.962	 0.028	 0.512	 0.903	 0.532	
Systemic		
sub-score		
Mean	 24.8/21.3	 19.9/25.5	 22.0/23.3	 21.0/23.9	 21.2/23.6	 22.4/24.8	 23.1/22.8	
p-value	 0.004	 <0.0005	 0.582	 0.044	 0.132	 0.119	 0.913	
Social		
sub-score	
Mean	 32.9/31.5	 30.3/33.8	 31.8/32.2	 30.9/32.8	 30.4/32.8	 32.2/31.7	 30.8/32.6	



































Depression	 Mean	 3.7/3.9	 4.9/2.8	 4.6/3.5	 5.1/3.2	 5.2/3.3	 3.8/4.1	 4.0/3/8	
p-value	 0.959	 0.015	 0.188	 0.054	 0.091	 0.940	 0.978	
Anxiety	 Mean	 6.3/6.5	 7.2/5.6	 8.0/5.8	 7.1/6.1	 7.2/6.1	 6.2/7.5	 7.1/6.2	
p-value	 0.944	 0.135	 0.053	 0.491	 0.237	 0.232	 0.816	
1	Independent	sample	t-test;	2	Mann-Whitney	U	test	
	


















-0.830	 0.216	 -0.078	 0.292	 0.424	 -0.102	 -0.026	 0.102	 -0.078	 0.021	 0.087	 -0.046	
p-value	 0.457	 0.054	 0.486	 0.051	 0.010	 0.360	 0.816	 0.363	 0.491	 0.860	 0.477	 0.702	
Anxiety	 Correlation	
coefficient	
-0.272	 -0.034	 -0.005	 0.274	 0.119	 0.162	 0.052	 0.152	 0.127	 -0.236	 -0.148	 0.053	






APPENDIX XIII – CORRELATIONS BETWEEN BASELINE WELL-BEING AND DEMOGRAPHIC DATA FOR THE SUPPORT GROUP 
Supplementary	Table	7:	Correlation	coefficients	between	fatigue	scores	(IBD-F	and	MFI)	and	continuous	baseline	demographic	variables,	support	group.	



















-0.137	 0.140	 -0.217	 0.329	 0.755	 -0.022	 -0.031	 -0.007	 -0.001	 0.369	 0.723	 0.307	





-0.503	 -0.065	 -0.470	 0.618	 0.380	 0.113	 0.269	 0.132	 0.258	 0.238	 0.386	 0.226	





0.243	 0.032	 0.280	 0.153	 0.329	 0.277	 0.161	 0.293	 0.373	
p-value	 0.065	 0.478	 0.121	 0.599	 0.935	 0.277	 0.558	 0.198	 0.281	 0.600	 0.270	 0.189	
Physical	 Correlation	
coefficient	
-0.421	 0.267	 -0.503	 0.728	 0.308	 0.103	 -0.027	 -0.038	 0.010	 0.098	 0.145	 0.316	





-0.405	 0.306	 -0.222	 0.095	 0.712	 0.172	 0.134	 -0.046	 0.127	 -0.003	 0.387	 0.193	





-0.165	 0.137	 -0.261	 -0.158	 0.422	 -0.091	 -0.355	 -0.169	 -0.320	 0.056	 0.282	 0.228	
p-value	 0.527	 0.614	 0.311	 0.735	 0.258	 0.728	 0.162	 0.396	 0.210	 0.855	 0.289	 0.433	
Mental	 Correlation	
coefficient	
-0.104	 -0.110	 -0.232	 0.385	 0.510	 -0.019	 0.166	 0.396	 0.275	 0.139	 0.176	 0.141	





















IBD-F	 Section	one	 Mean	 -	 9.4/6.7	 9.4/8.3	 10.0/7.8	 9.0/8.3	 9.0/8.1	 9.5/8.4	
p-value	 -	 0.104	 0.565	 0.228	 0.694	 0.618	 0.575	
Section	two	 Mean	 -	 35.7/25.7	 30.8/36.1	 36.7/33.0	 36.0/33.2	 34.6/34.4	 43.5/31.8	
p-value	 -	 0.400	 0.693	 0.786	 0.831	 0.989	 0.410	
MFI	 General	 Mean	 -	 15.3/15.0	 14.4/15.8	 15.0/16.0	 14.8/15.9	 16.6/13.6	 13.8/15.8	
p-value	 -	 0.885	 0.517	 0.618	 0.550	 0.103	 0.345	
Physical	 Mean	 -	 15.2/13.2	 13.8/14.9	 14.2/14.7	 14.8/14.4	 15.3/13.6	 16.2/14.1	
p-value	 -	 0.253	 0.542	 0.772	 0.856	 0.302	 0.123	
Reduced	
Activity	
Mean	 -	 11.8/9.8	 12.4/10.7	 11.8/10.8		 12.5/10.0	 11.4/10.9	 11.2/11.1	
p-value	 -	 0.307	 0.372	 0.600	 0.149	 0.765	 0.964	
Reduced	
Motivation	
Mean	 -	 11.2/11.2	 11.4/11.5	 13.3/11.0	 12.1/10.9	 11.2/11.9	 10.8/11.7	
p-value	 -	 0.986	 0.959	 0.165	 0.488	 0.718	 0.655	
Mental	 Mean	 -	 10.9/8.5	 10.4/10.2	 10.0/10.9	 10.9/9.7	 9.9/10.7	 11.0/10.0	

























0.515	 0.144	 0.292	 -0.604	 -0.519	 -0.196	 -0.241	 -0.102	 -0.225	 -0.460	 -0.252	 -0.208	





0.460	 0.060	 0.311	 -0.904	 -0.441	 -0.200	 -0.193	 -0.153	 -0.252	 -0.550	 -0.215	 -0.222	





0.493	 0.304	 0.298	 -110	 -0.504	 0.030	 -0.241	 -0.176	 -0.125	 -0.361	 -0.286	 -0.044	





0.446	 -0.325	 0.276	 -579	 -0.322	 -0.256	 -0.132	 -0.204	 -0.217	 -0.466	 -0.325	 -0.220	





0.247	 0.192	 0.238	 -0.736	 -0.159	 0.100	 -0.362	 -0.162	 -0.149	 -0.292	 -0.310	 0.088	





















Total	score	 Mean	 -	 164.5/176.5	 162.2/166.8	 163.5/165.7	 161.6/168.9	 166.2/166.4	 153.8/169.1	
p-value	 -	 0.409	 0.782	 0.896	 0.634	 0.831	 0.388	
Bowel		
sub-score	
Mean	 -	 52.7/5.9/3	 54.4/53.6	 52.8/54.7	 53.1/54.4	 53.5/54.3	 50.1/54.8	
p-value	 -	 0.114	 0.895	 0.741	 0.798	 0.364	 0.470	
Emotional		
sub-score	
Mean	 -	 61.7/62.7	 57.4/62.0	 59.2/60.1	 58.4/62.7	 62.7/57.7	 55.8/62.2	
p-value	 -	 0.892	 0.553	 0.902	 0.544	 0.417	 0.512	
Systemic		
sub-score	
Mean	 -	 19.5/21.7	 19.8/20.2	 20.7/19.6	 20.0/20.1	 17.9/23.1	 20.3/20.0	
p-value	 -	 0.501	 0.911	 0.746	 0.970	 0.113	 0.943	
Social		
sub-score	
Mean	 -	 30.6/32.8	 30.6/31.1	 30.8/31.3	 30.1/31.7	 32.1/29.3	 27.3/32.1	


























Depression	 Mean	 -	 5.8/4.3	 6.2/5.4	 5.5/6.1	 6.2/4.8	 5.2/6.3	 5.8/4.3	
p-value	 -	 0.445	 0.713	 0.773	 0.336	 0.581	 0.445	
Anxiety	 Mean	 -	 6.9/7.5	 9.4/6.8	 7.8/7.9	 8.4/6.9	 5.6/10.4	 6.9/7.5	
p-value	 -	 0.786	 0.284	 0.978	 0.502	 0.019	 0.786	
1	Independent	sample	T-test;	^due	to	small	numbers	of	males	in	this	group,	differences	in	gender	could	not	be	calculated	
	 	


















-0.464	 0.009	 -0.295	 0.448	 0.437	 0.161	 0.211	 0.232	 0.287	 0.212	 0.147	 0.126	
p-value	 0.061	 0.973	 0.250	 0.314	 0.240	 0.537	 0.417	 0.370	 0.287	 0.431	 0.632	 0.668	
Anxiety	 Correlation	
coefficient	
-0.169	 -0.463	 0.018	 0.099	 0.316	 0.070	 0.126	 0.003	 0.142	 0.135	 0.205	 0.096	






APPENDIX XIV – CORRELATIONS BETWEEN BASELINE WELL-BEING AND DEMOGRAPHIC DATA FOR THE INDEPENDENT GROUP  
Supplementary	Table	13:	Correlation	coefficients	between	baseline	fatigue	scores	(IBD-F	and	MFI)	and	continuous	demographic	variables,	independent	group.	




















-0.143	 0.143	 0.098	 0.499	 0.274	 -0.127	 0.093	 -0.160	 -0.132	 -0.010	 -0.024	 -0.252	





-0.280	 0.241	 -0.082	 0.423	 0.317	 -0.123	 -0.050	 0.000	 -0.160	 -0.023	 0.077	 -0.043	
p-value	 0.025	 0.057	 0.518	 0.009	 0.108	 0.334	 0.692	 0.998	 0.211	 0.862	 0.574	 0.751	
MFI	 General	 Correlation	
coefficient	
-0.223	 0.111	 0.092	 0.299	 0.286	 -0.141	 -0.035	 -0.237	 -0.275	 -0.028	 -0.126	 -0.344	
p-value	 0.075	 0.381	 0.466	 0.068	 0.149	 0.263	 0.781	 0.057	 0.028	 0.832	 0.356	 0.010	
Physical	 Correlation	
coefficient	
0.064	 0.076	 0.145	 0.403	 0.409	 -0.234	 -0.199	 -0.325	 -0.353	 0.124	 0.108	 -0.183	





0.125	 0.009	 0.164	 0.220	 0.315	 -0.181	 -0.086	 -0.231	 -0.306	 0.033	 0.105	 -0.275	





0.038	 0.178	 0.070	 0.207	 0.293	 -0.109	 -0.099	 -0.118	 -0.290		 0.047	 0.149	 -0.436	





0.033	 0.276	 0.288	 -0.068	 -0.025	 0.004	 -0.067	 -0.266	 -0.131	 -0.222	























IBD-F	 Section	one	 Mean	 7.7/9.2	 10.5/7.0	 8.4/8.4	 9.7/7.8	 8.0/8.5	 8.5/7.6	 8.8/8.3	
p-value	 0.112	 0.001	 0.889	 0.0721	 0.660	 0.502	 0.676	
Section	two	 Mean	 24.1/25.9	 34.7/18.7	 27.3/24.0	 10.7/22.3	 29.2/23.5	 26.3/17.8	 30.8/23.0	
p-value	 0.6082	 0.005	 0.858	 0.1111	 0.313	 0.205	 0.166	
MFI	 General	 Mean	 12.2/14.2	 14.5/12.2	 12.9/13.2	 14.1/12.6	 12.7/13.2	 13.4/11.5	 12.9/13.2	
p-value	 0.036	 0.041	 0.918	 0.172	 0.617	 0.162	 0.831	
Physical	 Mean	 11.4/12.0	 13.4/10.5	 12.2/11.4	 12.3/11.3	 11.0/11.9	 12.1/9.4	 12.8/11.3	
p-value	 0.558	 0.005	 0.576	 0.426	 0.466	 0.055	 0.186	
Reduced	
Activity	
Mean	 9.3/10.2	 10.7/9.1	 10.1/9.6	 10.2/9.5	 8.8/10.0	 10.0/7.9	 10.8/9.3	
p-value	 0.378	 0.092	 0.746	 0.460	 0.255	 0.107	 0.189	
Reduced	
Motivation	
Mean	 9.6/10.1	 11.0/9.1	 9.7/9.8	 9.6/9.9	 10.4/9.7	 10.1/8.5	 10.2/9.7	
p-value	 0.524	 0.033	 0.456	 0.572	 0.480	 0.195	 0.643	
Mental	 Mean	 9.3/10.6	 10.9/9.2	 11.4/9.3	 10.7/9.5	 9.7/.10.0	 10.0/9.3	 9.4/10.0	





























0.051	 -0.171	 -0.741	 -0.724	 0.043	 0.075	 -0.076	 0.122	 0.098	 -0.026	 -0.081	 0.357	





0.1171	 -0.083	 -0.630	 -0.678	 0.022	 -0.011	 -0.137	 0.125	 0.046	 -0.084	 -0.044	 0.487	





-0.010	 -0.099	 -0.567	 -0.503	 -0.056	 -0.014	 -0.072	 -0.020	 -0.005	 0.104	 0.002	 0.196	





0.1001	 -0.272	 -0.553	 -0.653	 0.115	 0.174	 -0.062	 0.211	 0.199	 -0.033	 -0.121	 0,239	





-0.016	 -0.154	 -0.512	 -0.697	 0.143	 0.091	 0.093	 0.074	 0.074	 -0.271	 -0.329	 0.331	




















Total	score	 Mean	 184.7/171.3	 160.7/190.9	 177.9/178.9	 163.9/185.3	 170.0/181.3	 177.1/186.8	 176.4/179.4	
p-value	 0.005	 <0.005	 0.935	 <0.0005	 0.169	 0.201	 0.505	
Bowel	sub-
score	
Mean	 59.5/51.4	 50.1/59.8	 56.7/66.7	 50.4/58.4	 53.0/56.8	 55.5/57.4	 55.1/56.1	
p-value	 <0.0005	 <0.005	 0.535	 <0.0005	 0.113	 0.511	 0.494	
Emotional	
sub-score	
Mean	 67.5/65.7	 60.3/71.0	 66.7/66.7	 61.6/69.0	 64.5/67.3	 66.1/70.0	 65.9/70.0	
p-value	 0.636	 <0.005	 0.737	 0.005	 0.492	 0.260	 0.756	
Systemic	
sub-score	
Mean	 24.7/22.44	 20.1/26.1	 22.7/24.1	 21.1/24.9	 21l8/24.2	 23.2/26.0	 23.9/23.6	
p-value	 0.050	 <0.005	 0.621	 0.007	 0.190	 0.134	 0.932	
Social	sub-
score		
Mean	 32.9/31.9	 30.2/34.0	 32.2/32.5	 30.9/33.1	 30.6/33.0	 32.3/33.4	 31.7/32.7	























0.001	 0.251	 -0.033	 0.302	 0.311	 -0.172	 -0.041	 0.133	 -0.115	 -0.009	 0.122	 -0.067	
p-value	 0.992	 0.046	 0.793	 0.066	 0.114	 0.171	 0.747	 0.289	 0.367	 0.946	 0.372	 0.615	
Anxiety	 Correlation	
coefficient	
-0.280	 0.036	 -0.005	 0.371	 0.046	 0.166	 0.051	 0.202	 0.136	 -0.307	 -0.187	 0.043	

























Depression	 Mean	 3.7/2.9	 4.6/2.5	 4.1/3.0	 4.9/2.6	 4.4/3.0	 3.5/2.5	 3.2/3.4	
p-value	 0.239	 0.064	 0.385	 0.013	 0.616	 0.353	 0.600	
Anxiety	 Mean	 6.2/6.0	 7.3/5.3	 7.7/5.5	 7.0/5.7	 6.6/6.0	 6.3/5.4	 6.2/6.1	
p-value	 0.726	 0.119	 0.155	 0.317	 0.736	 0.777	 0.663	
1	Mann-Whitney	U	test	
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